Form 8-K

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FDjvYigQTDf/3EDRE7Pm6GxQH0Oxr1QQ/nf1ZcG8Hn4ZNfcNftik5YGWJY2hRUTB ezwN+wFse+vgFI5DhgQzEg== 0001193125-07-224829.txt : 20071024 0001193125-07-224829.hdr.sgml : 20071024 20071024171554 ACCESSION NUMBER: 0001193125-07-224829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20071024 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20071024 DATE AS OF CHANGE: 20071024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSS WORLD MEDICAL INC CENTRAL INDEX KEY: 0000920527 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 592280364 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23832 FILM NUMBER: 071188740 BUSINESS ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 BUSINESS PHONE: 9043323000 MAIL ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 FORMER COMPANY: FORMER CONFORMED NAME: PHYSICIAN SALES & SERVICE INC /FL/ DATE OF NAME CHANGE: 19940318 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2007

PSS WORLD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

Commission File Number: 0-23832


Florida		59-2280364
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification Number)

4345 Southpoint Blvd.
Jacksonville, Florida		32216
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code		(904) 332-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Disclosure of Results of Operations and Financial Condition.

On October 24, 2007, PSS World Medical, Inc. (the “Company”) issued a press release in which the Company announced its financial results for the three and six months ended September 28, 2007. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. In connection with the press release, the Company has also made available certain supplemental financial information (“the Financial Supplement”) for the three and six months ended September 28, 2007, which may be found on the Company’s website at www.pssd.com. This Financial Supplement is included as Exhibit 99.2 to this report and is incorporated herein by reference.

In accordance with General Instruction B.6 of Form 8-K, the information included or incorporated in this report, including Exhibit 99.1 and Exhibit 99.2, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

The press release and Financial Supplement contain financial measures that are not in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company has provided reconciliations within the press release and Financial Supplement of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company provides non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures are intended to supplement the user’s overall understanding of the Company’s current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company’s core operating results or business performance. However, these non-GAAP financial measures are not intended to supercede or replace the Company’s GAAP results. A detailed reconciliation of the GAAP results to the non-GAAP results is provided within the financial supplement.

Item 9.01 Financial Statements and Exhibits.


Exhibit Number		Description

99.1		Press Release dated October 24, 2007 with respect to the Registrant’s financial results for the three and six months ended September 28, 2007.

99.2		Financial Supplement for the three and six months ended September 28, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 24, 2007


PSS WORLD MEDICAL, INC.

By:		/s/ David M. Bronson
		Name: David M. Bronson Title: Executive Vice President and Chief Financial Officer

EXHIBIT INDEX



99.1		Press Release dated October 24, 2007.

99.2		Financial Supplement for the three and six months ended September 28, 2007

EX-99.1 2 dex991.htm PRESS RELEASE Press Release

LOGO

N E W S R E L E A S E

Exhibit 99.1

Contacts:


For investors:	Robert C. Weiner	For media:	Brian C. Kosoy
	Vice President, Investor Relations		Public Relations
	904-332-3287		904-332-4175

PSS WORLD MEDICAL REPORTS RESULTS

FOR FISCAL 2008 SECOND QUARTER

Fiscal 2008 Second Quarter Highlights:

•

Consolidated net sales growth of 7.2% (11.2% excluding last fiscal year flu sales)

Physician Business net sales growth of 6.4% (12.2 % excluding last fiscal year flu sales)

Elder Care Business net sales growth of 9.1%

•

Consolidated earnings per diluted share of $0.22, including,

$0.01 per diluted share for temporary operational costs associated with new Florida pedigree law

$0.01 per diluted share to increase accrual for destruction of pedigree-related quarantined inventory

$0.01 per diluted share of integration costs for the Activus acquisition

$0.04 per diluted share reduction of accruals for management incentive programs

•

Physician Business operating margin of 6.5%

•

Elder Care Business operating margin of 5.1%

•

Consolidated cash flow from operations of $13.1 million

•

Repurchased 2.8 million shares for $49.4 million

•

Announced acquisition of an approx. 5% stake in athenahealth, Inc. (NASDAQ GM:ATHN)

Jacksonville, Florida (October 24, 2007) – PSS World Medical, Inc. (NASDAQ GS:PSSI) announced today its results for the fiscal 2008 second quarter and six months ended September 28, 2007.

David A. Smith, Chairman and Chief Executive Officer, commented, “We have traction and execution across the breadth of our strategic programs. Momentum has accelerated from strategy implementation to program execution and success in global sourcing, home care and pharmaceuticals. However, the fastest start to any strategy in our arsenal is healthcare information technology with athenahealth and Smartscan. These technology solutions will galvanize our customer relationships and value proposition, as investors continue to benefit from a combination of our innovation, service excellence and strategic investments.”

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 2

October 24, 2007

Net sales for the three months ended September 28, 2007, were $457.9 million, an increase of 7.2%, compared with net sales of $427.1 million for the three months ended September 29, 2006. Net sales for the three months ended September 28, 2007, for the Physician Business increased by 6.4%, while net sales for the Elder Care Business increased by 9.1%. Income from operations for the three months ended September 28, 2007, was $24.5 million compared with income from operations for the three months ended September 29, 2006, of $21.6 million. Net income for the three months ended September 28, 2007, was $14.5 million, or $0.22 per diluted share, compared with net income for the three months ended September 29, 2006, of $12.8 million, or $0.18 per diluted share.

Net sales for the six months ended September 28, 2007, were $896.8 million, an increase of 6.7%, compared with net sales of $840.2 million for the six months ended September 29, 2006. Net sales for the six months ended September 28, 2007, for the Physician Business increased by 7.0%, while net sales for the Elder Care Business increased by 6.1%. Income from operations for the six months ended September 28, 2007, was $39.0 million compared with income from operations for the six months ended September 29, 2006, of $40.3 million. Net income for the six months ended September 28, 2007, was $23.2 million, or $0.34 per diluted share, compared with net income for the six months ended September 29, 2006, of $23.7 million, or $0.34 per diluted share.

David M. Bronson, Executive Vice President and Chief Financial Officer, commented, “Profitable revenue growth associated with momentum in our key business strategies through the first half of fiscal year 2008 has been offset to some degree with costs of compliance with drug pedigree legislation. Acquisition integration and the investment in the launch of our healthcare information technology offerings have also been a drag on earnings in the first two quarters, but should turn positive in the second half of fiscal year 2008.

“We are reiterating our full year goals for fiscal year 2008 of $0.81 – $0.85 earnings per diluted share and $63 – $67 million of cash flow from operations. Our repurchase of 2.8 million shares during the second quarter represents an accretive use of cash and underlines our confidence in achieving continued growth in the business, while providing a nice return to investors.”

The Company has today filed with the SEC a Form 8-K that includes a copy of this press release and its related Fiscal 2008 Second Quarter Financial Workbook, which contains GAAP and non-GAAP financial measures, and is available on the Company’s website, www.pssworldmedical.com.

A listen-only simulcast as well as a 90-day online replay of PSS World Medical’s fiscal 2008 second quarter conference call can be found in the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations,” or at www.opencompany.info, on October 25, 2007, beginning at 8:30 a.m. Eastern time.

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 3

October 24, 2007

PSS World Medical, Inc. is a national distributor of medical products to physicians and elder care providers through its two business units. Since its inception in 1983, PSS has become a leader in the two market segments that it serves with a focused market approach to customer services, a consultative sales force, strategic acquisitions, strong arrangements with product manufacturers and a unique culture of performance.

Additional financial information pertaining to PSS World Medical financial results may be found by visiting the Investor Relations/Financial Information sections of the Company’s websites, www.pssworldmedical.com or www.pssd.com, respectively, under the heading “Events and Presentations.” If you should need assistance accessing the information, please call Investor Relations at 904-332-3000.

All statements in this release that are not historical facts, including, but not limited to, statements regarding anticipated growth in revenue, gross and operating margins, and earnings, statements regarding the Company’s current business strategy, the Company’s ability to complete and integrate acquired businesses and generate acceptable rates of return, the Company’s projected sources and uses of cash, and the Company’s plans for future development and operations, are based upon current expectations. Specifically, forward-looking statements in this Press Release include, without limitation, the Company’s expected results in GAAP EPS for the consolidated company; the expected operational cash flow in fiscal year 2008;the expected impact on earnings during the remainder of fiscal 2008 from the Company’s strategy to invest and participate in the marketing and sales of healthcare information technology products and services (HCIT); the expected impact on earnings during the remainder of 2008 related to the integration of acquired assets; as well as other expectations of growth and financial and operational performance. These statements are forward-looking in nature and involve a number of risks and uncertainties. Actual results may differ materially. Among the factors that could cause results to differ materially are the following: pricing and customer credit quality pressures; the loss of any of our distributorship agreements and our reliance on relationships with our suppliers and vendors; our reliance on a limited number of chain business elder care customers; the availability of sufficient capital to finance the Company’s business plans on terms satisfactory to the Company; lower revenue and earnings that may result from competition; the ability of the Company to adequately defend or reach a settlement on outstanding litigation matters and investigations involving the Company or its management; changes in labor, equipment and capital costs; changes in legislation and regulations affecting the Company’s business, such as the Medicare cliffs, changes in malpractice insurance rates and tort reform; future acquisitions or strategic partnerships; general business, competitive and economic factors and conditions; and other factors described from time to time in the Company’s reports filed with the Securities and Exchange Commission. Many of these factors are outside the control of the Company. The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company also wishes to caution readers that it undertakes no duty or is under no obligation to update or revise any forward-looking statements.

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 4

October 24, 2007

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Operations

(In millions, except per share and share data)


	Three Months Ended						Six Months Ended
	Sept. 28, 2007			Sept. 29, 2006			Sept. 28, 2007			Sept. 29, 2006
Net sales	$	457.9		$	427.1		$	896.8		$	840.2
Cost of goods sold		325.4			303.2			636.6			596.4

Gross profit		132.5			123.9			260.2			243.8
General and administrative expenses		77.3			73.4			160.9			147.1
Selling expenses		30.7			28.9			60.3			56.4

Income from operations		24.5			21.6			39.0			40.3


Other (expense) income:
Interest expense		(1.5	)		(1.3	)		(2.9	)		(2.8	)
Interest and investment income		0.1			0.3			0.6			0.4
Other income		0.5			0.4			1.1			0.9

		(0.9	)		(0.6	)		(1.2	)		(1.5	)


Income before provision for income taxes		23.6			21.0			37.8			38.8
Provision for income taxes		9.1			8.2			14.6			15.1

Net income	$	14.5		$	12.8		$	23.2		$	23.7


Earnings per share – basic	$	0.22		$	0.19		$	0.35		$	0.35


Earnings per share – diluted	$	0.22		$	0.18		$	0.34		$	0.34


Weighted average shares (in thousands):
Basic		65,806			67,453			66,300			67,381
Diluted		67,067			69,478			67,916			69,213

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 5

October 24, 2007

PSS WORLD MEDICAL, INC.

Condensed Consolidated Balance Sheets

(In millions, except per share and share data)


	Sept. 28, 2007		March 30, 2007
	*(Unaudited)*
ASSETS
Current Assets:
Cash and cash equivalents	$	17.0	$	46.7
Accounts receivable, net		232.3		222.8
Inventories		188.1		174.1
Deferred tax assets, net		9.3		8.8
Prepaid expenses and other		27.9		34.4

Total current assets		474.6		486.8

Property and equipment, net		89.3		88.6

Other Assets:
Goodwill and intangibles, net		139.7		137.1
Investment in available for sale securities		46.1		—
Other		70.0		62.5

Total assets	$	819.7	$	775.0


LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	149.8	$	131.3
Accrued expenses		33.3		37.2
Revolving line of credit and current portion of long-term debt		32.1		2.2
Other current liabilities		15.0		11.5

Total current liabilities		230.2		182.2
Long-term debt, excluding current portion		150.4		150.7
Other noncurrent liabilities		66.9		61.2

Total liabilities		447.5		394.1


Shareholders’ Equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized, no shares issued and outstanding		—		—
Common stock, $0.01 par value; 150,000,000 shares authorized, 64,688,716 and 67,179,475 shares issued and outstanding at September 28, 2007, and March 30, 2007, respectively		0.6		0.7
Additional paid-in capital		254.8		300.0
Retained earnings		103.1		80.2
Accumulated other comprehensive income		13.7		—

Total shareholders’ equity		372.2		380.9

Total liabilities and shareholders’ equity	$	819.7	$	775.0

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 6

October 24, 2007

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Cash Flows

(In millions)


	Three Months Ended						Six Months Ended
	Sept. 28, 2007			Sept. 29, 2006			Sept. 28, 2007			Sept. 29, 2006
Cash Flows from Operating Activities:
Net income	$	14.5		$	12.8		$	23.2		$	23.7
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		4.8			4.1			9.3			8.2
(Benefit) provision for deferred income taxes		(2.5	)		3.4			(2.3	)		7.8
Amortization of intangible assets		1.4			1.5			2.8			3.0
Provision for doubtful accounts		0.8			0.9			1.8			1.0
Non-cash compensation expense		1.2			0.5			1.9			0.8
Amortization of debt issuance costs		0.4			0.3			0.7			0.7
Provision for deferred compensation		0.3			0.4			1.7			0.9
Other		—			0.1			—			—

Changes in operating assets and liabilities, net of effects from business combination:
Accounts receivable, net		(10.2	)		(20.1	)		(8.2	)		(17.4	)
Inventories		(0.5	)		(1.5	)		(11.8	)		1.3
Prepaid expenses and other current assets		4.8			(3.8	)		5.6			(8.4	)
Other assets		(1.9	)		0.5			(8.9	)		0.3
Accounts payable		5.3			23.3			13.9			6.5
Accrued expenses and other liabilities		(5.3	)		7.5			2.7			5.5

Net cash provided by operating activities		13.1			29.9			32.4			33.9


Cash Flows from Investing Activities:
Payments for business combinations, net of cash acquired		(0.3	)		—			(15.1	)		(0.1	)
Payments for investment in available for sale securities		(1.5	)		—			(24.1	)		—
Capital expenditures		(4.6	)		(3.1	)		(9.5	)		(7.7	)
Proceeds from note receivable		2.7			—			2.7			—
Payments for non-solicitation agreements		(0.1	)		(0.3	)		(0.1	)		(0.8	)
Payments for signing bonuses		—			(0.1	)		—			(0.1	)
Other		—			—			—			—

Net cash used in investing activities		(3.8	)		(3.5	)		(46.1	)		(8.7	)


Cash Flows from Financing Activities:
Net proceeds from revolving line of credit		31.4			—			31.4			—
Proceeds from exercise of stock options		1.3			2.5			1.6			5.0
Excess tax benefits from share-based compensation arrangements		0.6			1.3			0.8			2.6
Proceeds from borrowings		—			1.0			—			1.0
Purchase of treasury shares		(49.4	)		(12.2	)		(49.4	)		(12.2	)
Payments under capital lease obligations		(0.2	)		(0.1	)		(0.4	)		(0.3	)
Other		—			(1.0	)		—			0.5

Net cash used in financing activities		(16.3	)		(8.5	)		(16.0	)		(3.4	)


Net increase (decrease) in cash and cash equivalents		(7.0	)		17.9			(29.7	)		21.8
Cash and cash equivalents, beginning of period		24.0			27.8			46.7			23.9

Cash and cash equivalents, end of period	$	17.0		$	45.7		$	17.0		$	45.7

-MORE-

PSSI Reports Results For Fiscal 2008 Second Quarter

Page 7

October 24, 2007

PSS WORLD MEDICAL, INC.

Net Sales Adjustment for Influenza Vaccine Sales

(In millions)


	For the Three Months Ended						For the Six Months Ended
	Sept. 28, 2007		Sept. 29, 2006		Growth		Sept. 28, 2007		Sept. 29,2006		Growth
*Consolidated:*
Net sales	$	457.9	$	427.1	7.2	%	$	896.8	$	840.2	6.7	%
Influenza vaccine sales		—		15.4				—		15.4

Net sales adjusted for influenza vaccine sales	$	457.9	$	411.7	11.2	%	$	896.8	$	824.8	8.7	%


*Physician Business:*
Net sales	$	320.2	$	300.8	6.4	%	$	626.4	$	585.3	7.0	%
Influenza vaccine sales		—		15.4				—		15.4

Net sales adjusted for influenza vaccine sales	$	320.2	$	285.4	12.2	%	$	626.4	$	569.9	9.9	%

END

EX-99.2 3 dex992.htm FINANCIAL SUPPLEMENT FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 28, 2007 Financial Supplement for the three and six months ended September 28, 2007

Exhibit 99.2

LOGO

Financial Data Workbook

For the Second Quarter of Fiscal Year 2008 ending September 28, 2007

PSS World Medical, Inc.

As of September 28, 2007

Current Fiscal Year

(in thousands, except per share data)


	Fiscal 2008
	Q1			Q2
Net Sales	$	438,910		$	457,930
Cost of Goods Sold		311,227			325,390

Gross Profit		127,683			132,540
General & Administrative Expenses		83,600			77,315
Selling Expenses		29,551			30,763

Income from operations		14,532			24,462
Interest Expense		(1,358	)		(1,533	)
Interest & Investment Income		528			114
Other Income		544			546

Income from Operations before Income Taxes		14,246			23,589
Provision for Income Taxes		5,559			9,106

Net Income	$	8,687		$	14,483

Earnings per share - Basic:
Net Income	$	0.13		$	0.22

Earnings per share - Diluted:
Net Income	$	0.13		$	0.22

WASO - Basic		66,793			65,806
WASO - Diluted		68,765			67,067

Net Sales by Segment:
Physician Business	$	306,245		$	320,171
Elder Care Business		132,665			137,759

	$	438,910		$	457,930

Billing Days:		64			63

Net Sales Per Billing Day:
Physician Business	$	4,785		$	5,082
Elder Care Business		2,073			2,187

	$	6,858		$	7,269

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

As of September 28, 2007

(in thousands, except per share data)


	Fiscal 2005															Fiscal 2006															Fiscal 2007
	Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total
Net Sales (1)	$	330,361		$	364,267		$	377,842		$	401,299		$	1,473,769		$	387,129		$	385,819		$	423,781		$	422,688		$	1,619,417		$	413,135		$	427,059		$	458,421		$	443,024		$	1,741,639
Cost of Goods Sold		234,585			258,945			268,675			288,209			1,050,414			276,654			273,512			303,707			298,219			1,152,092			293,233			303,203			335,186			310,007			1,241,629

Gross Profit		95,776			105,322			109,167			113,090			423,355			110,475			112,307			120,074			124,469			467,325			119,902			123,856			123,235			133,017			500,010
General & Administrative Expenses (2)		60,948			64,300			68,827			68,130			262,205			70,337			69,279			72,053			75,639			287,308			73,664			73,391			75,222			78,423			300,700
Selling Expenses		23,453			24,625			25,082			26,431			99,591			25,774			26,217			27,469			28,148			107,608			27,498			28,878			30,140			30,307			116,823

Income from operations		11,375			16,397			15,258			18,529			61,559			14,364			16,811			20,552			20,682			72,409			18,740			21,587			17,873			24,287			82,487
Interest Expense		(1,942	)		(1,817	)		(1,737	)		(1,360	)		(6,856	)		(1,509	)		(1,358	)		(1,561	)		(1,456	)		(5,884	)		(1,406	)		(1,336	)		(1,320	)		(1,284	)		(5,346	)
Interest & Investment Income		111			89			12			5			217			99			111			75			138			423			101			282			426			385			1,194
Other Income		343			252			378			261			1,234			457			1,750			435			504			3,146			469			429			517			591			2,006

Income from Continuing Operations before Income Taxes		9,887			14,921			13,911			17,435			56,154			13,411			17,314			19,501			19,868			70,094			17,904			20,962			17,496			23,979			80,341
Provision for Income Taxes		3,962			6,149			(525	)		7,184			16,770			5,271			6,529			7,080			6,957			25,837			6,949			8,187			6,376			8,348			29,860

Income from Continuing Operations		5,925			8,772			14,436			10,251			39,384			8,140			10,785			12,421			12,911			44,257			10,955			12,775			11,120			15,631			50,481
Total loss from discontinued operations		(1,708	)		—			1,295			—			(412	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	4,217		$	8,772		$	15,731		$	10,251		$	38,972		$	8,140		$	10,785		$	12,421		$	12,911		$	44,257		$	10,955		$	12,775		$	11,120		$	15,631		$	50,481

Earnings (loss) per share - Basic:
Income from Continuing Operations	$	0.09		$	0.14		$	0.22		$	0.16		$	0.61		$	0.13		$	0.16		$	0.19		$	0.19		$	0.67		$	0.16		$	0.19		$	0.17		$	0.23		$	0.75
Total loss from discontinued operations		(0.03	)		—			0.02			—			(0.01	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	0.06		$	0.14		$	0.24		$	0.16		$	0.60		$	0.13		$	0.16		$	0.19		$	0.19		$	0.67		$	0.16		$	0.19		$	0.17		$	0.23		$	0.75

Earnings (loss) per share - Diluted:
Income from Continuing Operations	$	0.09		$	0.13		$	0.22		$	0.16		$	0.60		$	0.12		$	0.16		$	0.19		$	0.19		$	0.66		$	0.16		$	0.18		$	0.16		$	0.23		$	0.73
Total loss from discontinued operations		(0.03	)		—			0.02			—			(0.01	)		—			—			—			—			—			—			—			—			—			—

Net (Loss) Income	$	0.06		$	0.13		$	0.24		$	0.16		$	0.59		$	0.12		$	0.16		$	0.19		$	0.19		$	0.66		$	0.16		$	0.18		$	0.16		$	0.23		$	0.73

WASO—Basic		64,890			64,358			64,305			64,656			64,547			64,877			65,392			65,779			66,546			65,643			67,310			67,453			67,054			67,059			67,219
WASO—Diluted		66,056			65,267			65,366			65,786			65,607			65,860			66,487			66,931			68,062			66,887			68,947			69,478			69,458			69,419			69,325

Net Sales by Segment:
Physician Business	$	216,705		$	237,370		$	243,439		$	261,502		$	959,016		$	250,544		$	255,422		$	290,010		$	290,844		$	1,086,820		$	284,438		$	300,813		$	329,160		$	313,109		$	1,227,520
Elder Care Business		113,656			126,897			134,403			139,797			514,753			136,585			130,397			133,771			131,844			532,597			128,697			126,246			129,261			129,915			514,119

	$	330,361		$	364,267		$	377,842		$	401,299		$	1,473,769		$	387,129		$	385,819		$	423,781		$	422,688		$	1,619,417		$	413,135		$	427,059		$	458,421		$	443,024		$	1,741,639

Billing Days:		62			65			61			65			253			64			63			62			64			253			64			63			62			64			253

Net Sales Per Billing Day:
Physician Business	$	3,495		$	3,652		$	3,991		$	4,023		$	3,791		$	3,915		$	4,054		$	4,678		$	4,544		$	4,296		$	4,444		$	4,775		$	5,309		$	4,892		$	4,852
Elder Care Business		1,833			1,952			2,203			2,151			2,035			2,134			2,070			2,158			2,060			2,105			2,011			2,004			2,085			2,030			2,032

	$	5,328		$	5,604		$	6,194		$	6,174		$	5,826		$	6,049		$	6,124		$	6,836		$	6,604		$	6,401		$	6,455		$	6,779		$	7,394		$	6,922		$	6,884

(1)

Quarterly net sales for fiscal year 2007 were adjusted in the fourth quarter of 2007 from previously reported amounts. During the fourth quarter of fiscal year 2007, the Company properly reclassified certain transactions from cost of sales to net sales. Such adjustments were deemed immaterial on quarterly net sales.

PSS World Medical, Inc.

As of September 28, 2007

Select^TM Net Sales

(in thousands)


	Fiscal 2003		Fiscal 2004		Fiscal 2005		Fiscal 2006		Fiscal 2007
Consolidated Select Sales	$	101,883	$	121,211	$	137,540	$	157,296	$	185,844

PSS WORLD MEDICAL, INC.

SEGMENT INFORMATION

September 28, 2007

(in thousands)


	Three Months Ended				Six Months Ended
	9/28/2007		9/29/2006		9/28/2007		9/29/2006
NET SALES:
Physician Business	320,171		300,813		626,416		585,252
Elder Care Business	137,759		126,246		270,424		254,942

Total Net Sales	457,930		427,059		896,840		840,194

BILLING DAYS:	63		63		127		127

NET SALES PER BILLING DAY:
Physician Business	5,082		4,775		4,932		4,608
Elder Care Business	2,187		2,004		2,129		2,007

Total Net Sales Per Billing Day	7,269		6,779		7,062		6,616

INCOME FROM OPERATIONS:
Physician Business	20,910		21,139		39,427		39,748
Elder Care Business	6,963		4,904		11,549		9,787
Corporate Shared Services	(3,411	)	(4,457	)	(11,982	)	(9,208	)

Total Income from operations	24,462		21,587		38,994		40,327

DEPRECIATION:
Physician Business	2,188		1,952		4,266		3,878
Elder Care Business	1,141		1,017		2,286		2,049
Corporate Shared Services	1,428		1,176		2,805		2,313

Total Depreciation	4,758		4,145		9,357		8,239

AMORTIZATION OF INTANGIBLE AND OTHER ASSETS:
Physician Business	767		750		1,549		1,522
Elder Care Business	638		698		1,285		1,396
Corporate Shared Services	1		29		30		59

Total amortization of intangible and other assets	1,406		1,477		2,864		2,977

PROVISION FOR DOUBTFUL ACCOUNTS:
Physician Business	781		433		1,385		369
Elder Care Business	68		490		415		646
Corporate Shared Services	—		—		—		—

Total provision for doubtful accounts	849		923		1,799		1,015

INTEREST EXPENSE:
Physician Business	1,236		1,028		2,309		2,045
Elder Care Business	1,958		1,959		3,917		3,917
Corporate Shared Services	(1,661	)	(1,651	)	(3,334	)	(3,223	)

Total interest expense	1,533		1,336		2,891		2,739

INTEREST AND INVESTMENT INCOME:
Physician Business	—		—		—		—
Elder Care Business	3		7		6		13
Corporate Shared Services	111		275		636		368

Total interest and investment income	114		282		642		380

PROVISION (BENEFIT) FOR INCOME TAXES:
Physician Business	7,690		7,971		14,657		14,927
Elder Care Business	1,928		1,167		2,957		2,322
Corporate Shared Services	(512	)	(951	)	(2,949	)	(2,113	)

Total provision for income taxes	9,106		8,187		14,664		15,136

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Current Fiscal Year Balance Sheet

(in thousands)

Consolidated


	As of
	6/29/07	9/28/07
ASSETS
Cash	23,954	17,041
Accounts Receivable, net	222,699	232,282
Inventory, net	187,499	188,087
Deferred Tax Assets	8,987	9,319
Other Current Assets	34,257	27,894

Total Current Assets	477,396	474,623

Property and Equipment, net	89,347	89,339
Intangibles, net	30,280	28,991
Goodwill	110,993	110,727
Investment in available for sale securities	—	46,147
Other Long-Term Assets	98,380	69,856

Total Long-Term Assets	329,000	345,060

Total Assets	806,396	819,683


LIABILITIES & EQUITY
Accounts Payable	144,572	149,827
Accrued Expenses	33,099	33,275
Current Maturities of Long-Term Debt	2,132	32,129
Other Current Liabilities	15,267	15,000

Total Current Liabilities	195,070	230,230

Long-Term Debt	150,527	150,449
Other Long-Term Liabilities	70,414	66,788

Total Long-Term Liabilities	220,941	217,237

Total Liabilities	416,011	447,467

Total Equity	390,385	372,216

Total Liabilities & Equity	806,396	819,683

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Balance Sheet Trend

(in thousands)

Consolidated


	Fiscal 2005				Fiscal 2006				Fiscal 2007
ASSETS	Jun-04	Sep-04	Dec-04	Mar-05	Jun-05	Sep-05	Dec-05	Mar-06	Jun-06	Sep-06	Dec-06	Mar-07
Cash	63,112	45,591	13,657	17,888	23,836	17,466	26,651	23,867	27,784	45,678	54,904	46,658
Accounts Receivable, net	182,639	197,423	209,342	217,350	208,642	213,585	207,659	208,964	206,405	225,536	219,822	222,776
Inventory, net	112,653	113,384	147,470	134,110	132,684	136,450	167,407	173,458	170,612	172,127	186,193	174,130
Deferred Tax Assets	38,594	33,301	32,206	29,014	29,113	20,183	14,298	12,959	11,181	9,042	7,379	8,776
Other Current Assets	13,596	10,016	18,567	19,451	22,182	25,822	27,937	33,827	32,876	39,288	37,329	34,434

Total Current Assets	410,594	399,715	421,242	417,813	416,457	413,506	443,952	453,075	448,858	491,671	505,627	486,774

Property and Equipment, net	70,792	73,362	76,453	81,105	84,173	86,840	86,475	87,663	88,214	87,291	85,885	88,627
Intangibles, net	10,737	12,824	22,419	21,858	21,217	34,427	35,395	34,345	33,350	32,343	31,186	29,758
Goodwill	71,631	71,646	79,542	85,617	86,273	103,420	105,452	105,521	106,519	106,819	106,971	107,366
Other Long-Term Assets	39,555	40,794	41,691	39,965	47,315	50,862	53,665	56,371	—	—	—	2

Total Long-Term Assets	192,715	198,626	220,105	228,545	238,978	275,549	280,987	283,900	283,066	281,388	282,105	288,201

Total Assets	603,309	598,341	641,347	646,358	655,435	689,055	724,939	736,975	731,924	773,059	787,732	774,975


	Fiscal 2005				Fiscal 2006				Fiscal 2007
LIABILITIES & EQUITY	Jun-04	Sep-04	Dec-04	Mar-05	Jun-05	Sep-05	Dec-05	Mar-06	Jun-06	Sep-06	Dec-06	Mar-07
Accounts Payable	105,057	105,608	127,465	109,649	115,455	118,953	141,622	139,227	122,449	145,767	162,338	131,330
Accrued Expenses	29,667	33,610	36,085	44,880	26,660	33,196	30,413	34,499	27,748	34,827	31,670	37,224
Current Maturities of Long-Term Debt	35,052	25,000	25,000	25,000	25,679	27,786	25,788	509	517	1,655	152,154	2,238
Liabilities of Discontinued Operations	4,809	405	—	—	—	—	—	—	—	—	—	—
Other Current Liabilities	12,982	13,360	9,296	9,701	12,661	11,883	11,837	13,639	12,490	13,917	10,730	11,440

Total Current Liabilities	187,567	177,983	197,846	189,230	180,455	191,818	209,660	187,874	163,204	196,166	356,892	182,232

Long-Term Debt	150,000	150,000	150,000	150,000	151,192	151,113	150,981	150,855	150,725	150,616	460	150,675
Other Long-Term Liabilities	23,629	25,225	29,359	30,310	35,870	41,179	43,509	49,433	54,274	57,781	62,302	61,207

Total Long-Term Liabilities	173,629	175,225	179,359	180,310	187,062	192,292	194,490	200,288	204,999	208,397	62,762	211,882
Total Liabilities	361,196	353,208	377,205	369,540	367,517	384,110	404,150	388,162	368,203	404,563	419,654	394,114

Total Equity	242,113	245,133	264,142	276,818	287,918	304,945	320,789	348,813	363,721	368,496	368,078	380,861

Total Liabilities & Equity	603,309	598,341	641,347	646,358	655,435	689,055	724,939	736,975	731,924	773,059	787,732	774,975

PSS World Medical, Inc.

Unaudited Operating Highlights

Current Fiscal Year

(in millions)


	Three Months Ended						Six Months Ended
	September 28, 2007			September 29, 2006			September 28, 2007			September 29, 2006
Net Sales:
Physician Business	$	320.2		$	300.8		$	626.4		$	585.3
Elder Care Business		137.8			126.2			270.4			254.9

Total Net Sales	$	457.9		$	427.1		$	896.8		$	840.2

Income from Operations:
Physician Business	$	20.9		$	21.1		$	39.4		$	39.7
Elder Care Business		7.0			4.9			11.5			9.8
Corporate Shared Services		(3.4	)		(4.5	)		(12.0	)		(9.2	)

Total income from operations	$	24.5		$	21.6		$	39.0		$	40.3

EBITDA (a)	$	31.2		$	27.6		$	52.3		$	52.4
Income from operations, as a percentage of net sales		5.3	%		5.1	%		4.3	%		4.8	%
Consolidated Return on Committed Capital (“ROCC”) (b)		27.2	%		27.5	%		22.9	%		26.4	%
Billing Days		63			63			127			127
Net Sales Per Billing Day (in thousands):
Physician Business	$	5,082		$	4,775		$	4,932		$	4,608
Elder Care Business		2,187			2,004			2,129			2,007

Total Net Sales Per Billing Day	$	7,269		$	6,779		$	7,062		$	6,616

Net Sales Per Billing Day Growth Rate:
Physician Business		6.4	%					7.0	%
Elder Care Business		9.1	%					6.1	%
Total Net Sales Per Billing Day Growth Rate		7.2	%					6.7	%

							Annualized
							September 28, 2007			September 29, 2006
DSO (c)
Physician Business								42.6			40.9
Elder Care Business								50.7			55.3
DOH (d)
Physician Business								48.8			48.2
Elder Care Business								56.1			50.8
DIP (e)
Physician Business								44.9			43.5
Elder Care Business								27.9			29.1
Cash Conversion Days (f)
Physician Business								46.5			45.6
Elder Care Business								78.8			77.0

							As of
							September 28, 2007			September 29, 2006
Operational working capital (g)							$	270.5		$	251.9
Net Debt:
Bank debt							$	31.4		$	1.0
Other debt								1.2			1.3
Convertible senior notes								150.0			150.0
Less: Cash and cash equivalents								(17.0	)		(45.7	)

Net Debt							$	165.6		$	106.6

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

EBITDA Calculation

Current Fiscal Year

(in thousands)


	Fiscal 2008
	Q1			Q2
Net Income	$	8,687		$	14,483

Plus: Interest expense		1,358			1,533
Less: Interest and investment income		(528	)		(114	)
Plus: Provision for income taxes		5,559			9,106
Plus: Depreciation		4,595			4,758
Plus: Amortization of intangible assets		1,458			1,406

EBITDA	$	21,128		$	31,172

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

EBITDA Calculation

(in thousands)


	Fiscal 2005															Fiscal 2006															Fiscal 2007
	Q1			Q2			Q3			Q4			Total FY 2005			Q1			Q2			Q3			Q4			Total FY 2006			Q1			Q2			Q3			Q4			Total FY 2007
Income from Continuing Operations	$	5,925		$	8,772		$	14,436		$	10,251		$	39,384		$	8,140		$	10,785		$	12,421		$	12,911		$	44,257		$	10,955		$	12,775		$	11,120		$	15,631		$	50,481

Plus: Interest expense		1,942			1,817			1,737			1,360			6,856			1,509			1,358			1,561			1,456			5,884			1,406			1,336			1,320			1,284			5,346
Less: Interest and investment income		(111	)		(89	)		(12	)		(5	)		(217	)		(99	)		(111	)		(75	)		(138	)		(423	)		(101	)		(282	)		(426	)		(385	)		(1,194	)
Plus: Provision for income taxes		3,962			6,149			(525	)		7,184			16,770			5,271			6,529			7,080			6,957			25,837			6,949			8,187			6,376			8,348			29,860
Plus: Depreciation		3,482			3,427			3,727			3,605			14,241			3,316			3,468			3,673			3,475			13,932			4,094			4,145			4,215			4,296			16,750
Plus: Amortization of intangible assets		836			935			1,278			1,488			4,537			1,361			1,389			1,677			1,871			6,298			1,505			1,472			1,468			1,463			5,908

EBITDA	$	16,036		$	21,011		$	20,641		$	23,883		$	81,571		$	19,498		$	23,418		$	26,337		$	26,532		$	95,785		$	24,808		$	27,633		$	24,073		$	30,637		$	107,151

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Return on Committed Capital (ROCC)

Current Fiscal Year

(in thousands)

Consolidated


	Fiscal 2008
	Q1		Q2
Quarterly Average Committed Capital (1)	363,905		387,926

Return on Committed Capital - Quarterly (2)	18.2	%	27.2	%

Return:
Net Income	8,687		14,483
Add:
Provision for Income Taxes	5,559		9,106
Interest Expense	1,358		1,533
Amortization	1,458		1,406
Interest and Investment Income	(528	)	(114	)

	16,534		26,414

Committed Capital:
Total Assets	806,396		819,683
Less assets excluded:
Cash	(23,954	)	(17,041	)
Goodwill and Intangibles, net	(141,273	)	(139,718	)

Total Liabilities	(416,011	)	(447,467	)
Plus liabilities excluded:
Current debt	2,132		32,129
Long-term debt	150,527		150,449

	377,817		398,035

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.

PSS World Medical, Inc.

Return on Committed Capital (ROCC)

(in thousands)

Consolidated


	Fiscal 2005										Fiscal 2006										Fiscal 2007
	Q1		Q2		Q3		Q4		Total FY 2005		Q1		Q2		Q3		Q4		Total FY 2006		Q1		Q2		Q3		Q4		Total FY 2007
Quarterly Average Committed Capital (1)	247,761		260,802		280,166		303,738				316,837		322,662		325,748		330,989				340,070		341,619		331,779		338,812
Annual Average Committed Capital (2)									274,084										321,764										341,411
Return on Committed Capital - Quarterly (3)	20.3	%	27.0	%	24.1	%	26.7	%			20.4	%	24.7	%	27.8	%	27.9	%			24.4	%	27.5	%	23.9	%	31.1	%
Return on Committed Capital - Annual									24.6	%									25.4	%									26.5	%
Return:
Income from Continuing Operations before Extraordinary Loss	5,925		8,772		14,436		10,251		39,384		8,140		10,785		12,421		12,911		44,257		10,955		12,775		11,120		15,631		50,481
Add:
Provision for Income Taxes	3,962		6,149		(525	)	7,184		16,770		5,271		6,529		7,080		6,957		25,837		6,949		8,187		6,376		8,348		29,860
Interest Expense	1,942		1,817		1,737		1,360		6,856		1,509		1,358		1,550		1,467		5,884		1,406		1,336		1,320		1,284		5,346
Amortization	836		934		1,278		1,488		4,536		1,361		1,389		1,677		1,871		6,298		1,500		1,477		1,469		1,462		5,908
Interest and Investment Income	(111	)	(89	)	(12	)	(5	)	(217	)	(99	)	(111	)	(64	)	(149	)	(423	)	(101	)	(282	)	(426	)	(385	)	(1,194	)

	12,554		17,583		16,914		20,278		67,329		16,182		19,950		22,664		23,057		81,853		20,709		23,493		19,859		26,340		90,401

Committed Capital:
Total Assets	603,309		598,341		641,347		646,358		646,358		655,435		689,055		724,939		736,975		736,975		731,924		773,059		787,732		774,975		774,975
Less assets excluded:
Cash	(63,112	)	(45,591	)	(13,657	)	(17,888	)	(17,888	)	(23,836	)	(17,466	)	(26,651	)	(23,867	)	(23,867	)	(27,784	)	(45,678	)	(54,904	)	(46,658	)	(46,658	)
Goodwill and Intangibles, net	(82,368	)	(84,470	)	(101,961	)	(107,475	)	(107,475	)	(107,490	)	(137,847	)	(140,847	)	(139,866	)	(139,866	)	(139,869	)	(139,162	)	(138,157	)	(137,124	)	(137,124	)
DTA from sale of Imaging Business	(28,444	)	(26,923	)	(26,746	)	(15,758	)	(15,758	)	(10,487	)	(6,184	)	(912	)	(3,614	)	(3,614	)	—								—
Total Liabilities	(361,196	)	(353,208	)	(377,205	)	(369,540	)	(369,540	)	(367,517	)	(384,110	)	(404,150	)	(388,162	)	(388,162	)	(368,203	)	(404,563	)	(419,654	)	(394,114	)	(394,114	)
Plus liabilities excluded:
Current debt	35,052		25,000		25,000		25,000		25,000		25,679		27,786		25,788		509		509		517		1,655		152,154		2,238		2,238
Long-term debt	150,000		150,000		150,000		150,000		150,000		151,192		151,113		150,981		150,855		150,855		150,725		150,616		460		150,675		150,675
Liabilities of Discontinued Operations	4,809		405		—		—		—		—		—		—		—		—		—		—		—		—		—

	258,050		263,554		296,778		310,697		310,697		322,976		322,347		329,148		332,830		332,830		347,310		335,927		327,631		349,992		349,992

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Annual Average Committed Capital equals the sum of the committed capital of the most recent two year ends, divided by two.

(3)	Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences.

PSS WORLD MEDICAL, INC.

Footnotes

(a) EBITDA represents net income plus provision for income taxes, interest expense, depreciation, and amortization of intangible assets, less interest and investment income. Management reviews EBITDA when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes EBITDA is an important measure of liquidity.

(b) ROCC equals return divided by average committed capital. Return is annualized for quarterly calculations. Management reviews ROCC when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes ROCC is an important measure of profitability and return.

(c) DSO is average accounts receivable divided by average daily net sales. Average accounts receivable is the sum of accounts receivable, net of the allowance for doubtful accounts, at the beginning and end of the most recent four quarters divided by five. Average daily net sales are net sales for the most recent four quarters divided by 360. Southern Anesthesia & Surgical, Inc. (“SAS”) accounts receivable balance of $1.4 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(d) DOH is average inventory divided by average daily cost of goods sold (“COGS”). Average inventory is the sum of inventory at the beginning and end of the most recent four quarters divided by five. Average daily COGS is quarterly COGS for the most recent four quarters divided by 360. SAS inventory balance of $3.9 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(e) DIP is average accounts payable divided by average daily COGS. Average accounts payable is the sum of accounts payable at the beginning and end of the most recent four quarters divided by five. SAS accounts payable balance of $3.8 million as of September 30, 2005, has been excluded from the Fiscal Year 2006 calculation.

(f) Cash Conversion Days is the sum of DSO and DOH less DIP.

(g) Operational working capital equals accounts receivable plus inventory minus accounts payable.

GRAPHIC 4 g19662g62l45.jpg GRAPHIC begin 644 g19662g62l45.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_ MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!Z`.D#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`****`"@G'Z#H3U..WZGH!R>*@NKF&SMY;FX=8X88WED=B`%2-&=V)8A5 M5$5G=F*HB*SNRHK,/YS/VIO^"Q'Q8^-_QPNOV)?^"0'@C0_V@_CA:R7<7Q-^ M/FN68U'X&_!O2K/4(=(U+7=,U1;NVTSQ*=`OI4GO?%=Y)>>#X;O[#HOAJQ^( MFO:J=*T3V,GR+,L]K5J.`ITU##47B,;C<56AAYU2XM89KV?8YAM8W:>4)(4C812[.@TO4[36=/LM4L3YABGBDC3\[/V0O\` M@GAX5^!6K0?&OXX^/?%/[5'[8&JV./$W[0OQ9F76+OPY)J=G:G6_#/P1\+75 ME#HGP=^'LMR+F&U\/>%+&VO)=/DCL-4U.ZM[.QL=-^XO%%_\2K22Z7P9X9\' M:XB0Q&S_`.$D\"+/DQM#"4: MSHX+%RQ\*:7/B_8RP]&K)7Y_J]&I^_\`9)V5.K6]G4JQUEA:,GRCP^+Q7U;Z MSC\++"N6L<+053'8BC'HJWU6$U.KOST\/"I"FTE&O6O<]`KFM?\`&?A'PJ&/ MB;Q/H'A\+;&\)K2'RDOM8^$'C?X3>+["VS<21SW1L?B%XL^#OB>_L8HXDF63 M2O#=QJ<\%TF=$M;A+R/2N%O_`/@HG^S'X5U.PT/XO^(_&W[.^N:AC['IO[0/ MPN^(/PILKP*L4LLVF>+?%'AB#P+KEK;,LUO>7.A>*[^*RD20W3PKMFAX'.$? MCDH.VG.^37H[R235^EU=II.YYN)XIR7#QDL3F-+*)7BHUL\PF+RK#R'KV4+$,R M.T=MJ$K"./D22$;$975V!CD"^@VU]:7EO#=6DZ75M<1Q2V\]OF6*:*=5>&6* M1`4>*1'5EE!\LKN;<`K%?GG4?A3^RQ^TGH-MXAU7P+\$/C;X;U5S-9Z[>>&O M`'Q!TO475+4>?9ZNUAJ]K<-MLK607%I=>=!):V[!XYK"U%G\J^)?^"1_['%Q M>3ZQ\+M"^(_[.GB&YE\V77_V?/BUXY^'K5I3490GA*;R?.,+6YX/FBZN.PU-\T7[2Q^FXD4ML& MX-C/*.HZ*>&90I.&Z`YR''6-PKZ_"3XB_LN_\%7/V;K--:_93_;`G_:7\,:- M:O.?A7^TGH_A_5O&][%9H7M;*Q^(FJ6<4^O7UQ!#!974U_XN^&T,SEKQKU)D MM/['\G\`?\%P/'7P;\=0_!W_`(*(?LT>*/@9XPM_LS7'BWP7I.JOH1TZZ_=V MVKS>"]=-YJ9T$-:7`77/!_B?QQ'J4C74-CI-LUA.MME+&4H.U:%6BEO4J1C* MBW=*RK4I5*<7JKQJ2C*+=FKVO\OB?%O)LBQ=+!<;Y1G_``1*O.-*AF>=X*E7 MX`"0"202`,GN%8_12>QKHC*,XQE!J49*\6G=27DU MOL_N9^FX3&83'X:CC,%BC.=*K3E%74X M3E!K5-H=1115'2%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!2,P52S$* MJ@LS$X``&223P`!R2>@I:_-G_@K3^V%IW[$?["?QP^+Z:Y=:+X[U/P[>_#;X M/OI=Y!::XWQ9\?:7J6E^$M1TDW5I>6LC^$$BU7XA:BES;3POH?@W5QM#A9(> MS+\#B[224I)R;:22;;T.3'8VAEV#Q. M.Q4U3P^$H5<15F^D*4)3EYMM1M%)-N322;=C\$O^"V/_``42^-?[3_[1&F?\ M$A?V"I;[4?%_B_Q'9>`OC7XK\-ZI]FG\0:YJFFRW>N_"*WU:UL_,T;P1X2T, M7>K_`!QUM;\""WTO6_"FL_V=I?A_QC9WG[Z_\$S?^"<7PF_X)Q?`#0_AGX-M M=+UWXCZW8:9J?QC^*BZ5!9:Y\0/&$4-R[AK@P17T/A'P])J-_IW@OP_,8X=( MTV26YN(9M:U+5;^Y_G:_X-9/V/=7U34?C;^WS\08[;4[G5+Z[^#WPOU77(-0 MU7Q3^U*^O;7Q7:I?Z;;6-Y:W? M]H2\JIY&5'!!!Z=P0I!]BJD="!TK]'\0,90X?A3\.LCFHY=DOLIY_BZ:Y*N> M<1NG%XNKBY)7G1R]\N'PV'O*EAY^U4;RC'D^'X+PU?.93XUS:#ECVNGB2Y M9M*\0_#[Q!?W<\#(1:VXU_3?B)IB6DT;X>XOE\/723;7$%A:>9&;;Q#QM\9O MVDOA1I[ZUKG[,J_%OPY8)+)J&/AW:7S2J M97BT?1OB-K^J@1M^XVADMOL`N@.TLH;CY2P!Y#$<9SR$BG#3%$P"F. M-E`V`%%("@K\H!&``8T^7IE%X^48_+&G:SE))ZZ)?^!)-635MDDI;/2Q]7C< MKK8A3E@\VS'+,4XM4Z]"6&Q4(-[*6%S'#8RA*GS).4:<:,VKQC5AHU\A_LY_ MMT?LZ?M/7NK>&_A_XNNM&^)'AD7*^,?@_P#$'1M4\"?%?P?=6$\5IJUGKG@S MQ#:V=^9-&O9DM-7NM*;4],T^Y=+>YOX[E9X(/I7Q=X(\&_$/0M1\+^//"?AO MQGX)/#^IVK8=[2_TG6[.[T[4+5]Q5TGM71LG(61%,?Y> M?\%1?^">]S^U/\/=/^(7P)C\,>`/VG/AC?\`_"2^%_'5A9W'ASQ5XMTO3=*D MMU\"OXS\//9:AIUTTT=E=^%=:U9-53P]?6CV=A+H%GK6IZO99'_!)7]OF3]J M;X97WP?^)\VN67[2WP(L+#P_\3+;Q5Y34; M*;2?%NEOI!N?#^L?9?[1U2^?5(YX>:%27MGAZ\5[]W0J)6A545%R7)[SA.%V MY)RDG:,HM)\J^%P'%^8X'BA+HQEB<-*%-JC#S_\`:!_X)/Z[X`OI_C#_`,$U MOBEKO[*GQ8ME-SJ7P\TGQ'JMO\'/'DD9-Q';WVB26^K6&D7'VF.W,5M?Z-K? M@I_LUNMQX7EL MNC>$[_Q$\]K]CL/&VD06\EKX,U+4[.]M[RS\4V-TWP_UB*0:BC>%](GTQ7_H M9K^>/_@O7^QA)\4/@Y9_M0>`?#6D-XU^"<9_X6!>Z=H]T/$^M?"F401--)>V M$+)?VO@'4[E]>9-0B=-*\/7?B748]5T^WTZ>UNL,13JX:$J^!B^:/OU<,I2= M*M!6/KX7*XRC1RC-L-2]KC_`*YE=.E/$NC-5*-:M.?MOZ&8Y%D4,I)! M"L,JRY#J&4CUIK?AS4_)8QO>:3?6DMW!FSN6>W*+%^6'_!"W M]LJ[_:%_9NN?@WXXU_4M6^*'[/9L-!DO-8N[*:[UKX=:A+??\(1<612PL;FX MB\.6EC=>"]0>[.IW:1Z)I.IWFJ_:==2PTW]SAR`?;W_J`?S`/M771JPQ%&%2 M%I4ZL-4US+M*+4DKVE>.UTTS]0X;SS(?$G@[+LXCA:&-RCB#+U+$9?C:4,13 MC)WHXS`8RC4AR3GAL1"KAJL90Y92IN2BDU;^'+]J[]EO]J3_`((U?''1_C'^ MS_\`$GQ'_P`*I\5ZK)IOA+QS;)!)'.BB#4A\,?B_H1T_^PM:NMEM]HTZ6[LC MH_B:WTR?7M(M])U;0;G3_#7[D?LU_P#!2/7/VQ/@'J?Q@^$-LME^T9^SWH9U MGXT_LS7]WI[Z/\7]`CT^&;4-3^'6J75G+J6C7E\]I?W'@G7(6:+1/$(3P3X_ MTO5=+O?#GB72_P!8OC[\&?!G[0'PC\>_"+Q]I.D:OX7\<^&=5T.^AUBS%Y!9 MW-S;YTO6K9%FL[B'4]`U*.UUO2;VSU+3;ZPU+3[2[T^_T^_AM=2L?\\FQU?X MT_L$_M)^-=*T_5-8\&?%#X7WWQ`^&NIW6CNNER3P:CIVH>&/M,,4VEW%O>Z! MJMM>6?BG1VN+*:&18]$U:SDL;JVT_4=*\>KS9574J:E+!XEN'L];4*M^=.E! M/E;TE)\RM**Y=9-)_P`G<;0S#Z.7$^%Q.1X[,EX6<:5L11Q63TZM6M+A3-*< M:,I8A4:>(?^A/^SA^T!\//VG_`(,^ M!_C=\+KRXNO!OC;2S=6,.H0QVNK:7>V4\VFZQH6L6<+206NK:'K%EJ&DZA%; M3W%J+FQE:UN)[=D>O&HKJ+#FSGU/3K(>)38*8)=-76UM-0@M-2M[VWLOH/2/ MVB#\%/VBM+_9A^-FI7MI!\5([_7OVKR7>B>,([6ZM5U;X0:K?ZEI\& MI6_Q!\*I=V\FF7&JZQXA?QKIE_:7`UFTUN1/#]EZ]*<3X?^R,7Q!EN3O%JI'V-#"YMF=## MK#86JI)1PBQ^(K*EA%6E&$<16P^"G-5ZU*,_O"BD#*V<$'!(."#@@E2#CN&! M4CL00>0:6MC[T****`"BBB@`HHHH`****`"BBB@`HHHH`"X^-ISP..V>X]01CU/&!SD8 MR/\`)R_;)^)I_:5_X*5_'+X@>(KAM>T;Q[^U7KND60N99F1_A[IOQ"@\'>#] M(6[6**7[-8>`])T724G@:S5([4M;1V<<4:V/[AX"Y/'&\68W.*T%.APYE-;& MQBTI,=;UE#ON)GAC@AM?,:.WBC@^Z:JVJ ME8H_DV`)@@Y#*<+P!Y:?(<<`K&4"JAC7`CALD@#)SU`X!)R2`.`"<9/)Z*,L MQ"@D?B^+QE?,,9BL?B9.IB,;B:^+K3;EA:,%]FEAX1I4XVN[%/% MUSX9UJWMH[=8;O3+?Q)X:U)('NWBCU;0KF[TV\0QB]N2ESX9\0^$]1N9C9_V MQJ.J66FZ?96O@^H_%S]H+X=W4T7C;]G?5/B;X=B"M;>-/@-XL\.ZKJ*`-+\*>+[NYAC9=-T#Q5<%-$;7UN3<68\*ZE=Z;XI MN38WVH6&C7FBV[ZG7K"2Q%RJ9#D*S#RW4_,/E+DJ,-@$88[@58$`HPY*U MY+EBFO=O9.S5[K1=&KK1VT=FO-Q%*CC*M98#.*V!Q=&JJ>)6%KX:O[.K*/-3 MI8C`XREBJ-.4U'VB4*6&KSC)U(5>6HW/XZU+]N[]G;P[&/\`A8VM^,_@]YF6\D8CFE=/$?B[P'I_A/4+.!5EDFU32M>O=,BC@N)6OXC8 MZDVG_P`[_P`6/BG\!/@K_P`%G?@/^T/^S]\9?A?XD^'/QVG\/Q_%34/!?C#P MMJWAGPYXA^(5SJ?P[\6V_B631Y+RWT:"\23PQ\1M2N=>_LE[;6)+S6KUK6TM MY+JP_KD:.W1-S11H@ZDQJ`H+JV3@?*-ZH[,%/^"C'_!9 MA3X6\&>&]<_9X_94LH],^(5Y-H&DS^%?%-YX6O?$%V9-1TV6P?2O$;>+_BCK M,VEVXN8[N/7?!WA74]4DCM[:T-M8>=CW/_9H05=?9O-?'W[:G[#]II.N^&?'?[4?[.5M:ZEID^DZWH M-_\`%WP%=7UQIVMVQM'@GT2'6YK^:SO[2XE61OLZJ+[M/"4+2SZ_K M`L='TV*5_+?5+VTSL:-9K'ME&KRR:=*5HMOF3C%)7O*5I2;271)7[V:3_3\Q MQ?&^#P6*Q6+GP7AL)AL/7KXNOB)9S6HTL-1I3J5ZE2G[.@I4X4X3E/FJ17(M M;W:/Y!_^"<7[2/A#]B;]O%_%EQXAU#6O@^T?Q0^&&OZEX/TZX\17'B;PE-'? M7'@O4-'TNP@BDU@:CXL\-^#+V(V\<+KIUS=7*(I5UA_I,U;_`(*R_%WQX([; M]E?_`()R_M4?%*)T&SQ5\0_#]Y\)_!A#0B:&XT[5H]#\8V&JVKQ203+#>:EX M=GDMIXVW6H,D]M^(W_!"3X#ZQ\:?VWM3^/%_IMM#X1^!MAXC\5ZE-;V-I#I3 M>._B#INN>%_#/A^SM'@(2)=/U#Q1K]L\#M+IH\-6=JXBW1"U_ME2&-50;$)4 M*,[$!RNSGY450:,'R&^(J8'BRKPID&.XGSC%930PF18''YD\ M(GA*%>>&QN;U,9@\-A7C:&,HTJ3RJM55:G7KRKS=50I_A9)X6_X+3_M5PQV' MBGQ7\)OV`?AKJ#2"]MO!MM;_`!&^,CZ?=R8C#7=MJ&L6-H_E2BZ%SI'B_P"& M^MZ;*L<16&5;V'3?YUO^"JO[%OA[]B?XU>`/!VA?$/QK\3+OQ]\,8O'WBSQ- MX\:UDUJ^\77/C+Q7H^J7D#VUO'(NGWUII>FS^3J=WK&KKJ7]IW-[K$JW4&G: M7_?U)Y$"%V145%)RL><`!>@1 M)=>#_@[I6G_!;1+A+F-K*[U/PQJFLWOC'4XI`$M8K9O&>LZYH\-Z97MI]*T* MQOS=16CQV]C&:T80PRG*I5J3]K%4Y5JCDVY<[GR0BHTX.RC=QC!6NDXMJ_F? M2=X1X?X?\/(8K'9IGG$?%>89QEV!RO,,^S:KC,33?.\3C5@\MP[PF38##O"T M94JDL!E>&LZF'IU)/VD>;^JK_@C;X^UCXA?\$ZOV>[[7I)I]1\,:;XG^'J33 MK@G1_`/B[6_"_AB",DL[16/A;3=$TY6=V<&S9"(E18(OSJ_X.&OBIH&F:%^R M]\/?"6K1-\=])^+:_$KPWI^B-%=^*M#TNSTJ72=)U?[)&DT]G)JWBZ31D\/- MRVDLDVA70M/G+P!_P5.\'_`+(_[,7P?_8M_8G\&:I^T/\`'+1O M#DUC?^.H?#GB&3P4_P`3/%NJZIXF\91^#O#T.FVOC;XGW&D>(-1U.TT:.+3] M!T:]M;+2;W1]5U;2[5K"R^I?V`_^"7'QL\;?&/3/VX_^"B&NW7C;XJSWEAXI M\(_#3Q7+]IU;0?$>FWL4WA[Q+XQAL;6TT+2QX;M[2VN?!OPYT2!M!\.%['[3 M#I5UHUEH&CZ2F\3AX8*E*-2I[.E#$UU?V5)J,95)1E#24KT>VJ MM>^NG\]^-]6<,7PVH_\`+NEF%6+U^)U<%\M/9QZWW/\`9B\"^)M)\;>#_"OC M30+F&^T+Q;X=TCQ-HEY%+!,EQH^OZ=::IIDT4EL&MY([BSN(I2T$KP;L+"3$ M$6+K:_'S_@A'^T0?VBO^"9/[-NH7UQ#-XB^%'AFY^`OB2&($X MY9%@@66YU'X<6G@K6[UF7>+S4IE\VZ(>2/\`8.OYGS?+JN3YKF655[>VRW'X MK`S:UC)X:M.BIQ>EX34%.$OMPE&?VC]URK'4\SRS+\QI24Z>.P>'Q4)*^U>E M&JTTTFI1E)PFFDU*+4DI71SOBGPIX6\::%J7AOQEX?T3Q1X:U:T>SUC0/$>F M6.LZ'J=BW,EKJ6EZE#F7VI`16%KH MOPYF\'LTEI;-IUK%?0PW-C^DOBCPO!XLL7TR]U;7M/TZ:*6*Z@\/ZO>^'KNZ M$BX4MKFC2V7B+3S`X26&70M7T>Z#JPEN98RJ)X]8_LT_L^>%=>?XEZCX`\*Z MGXOT6WN+I?B;\1/,\=^--#T^WC,ESY/Q!^(=YXB\2:-I-M9PH)8;36;'3[:V MMHL)#;6-A'8^=**E%V?ONR^TFDMFI1E&2:O>-FM5KI9/Q.(;1BJ66Y;+$ M4HM8?-,3C,=@\9@;RYW/"5LKAA\PBE*\YTZ&:8#VC>M5-WC^%/C3XO\`_!6W M]K3P/X^^#O[.>F^']>^%5WIIM=)_:[E^%OBO]ESQ!\0_#UR6%U8>"=(\=^,[ MV2,:WY4NF1>*?#&B:/:P6L-T4U#P]?M9ZG;]_P#L)OB'K,6G0QS^(KRU\.Z+I(MX[V:&&VT? MPE#/''H&F2;$DN=5&IR-^U/C']HCX'_#:>XTS7_B%X>76;1)6O/#.AS7?BOQ M;"+6=K:XFE\'^$K+6_$21P3QW5O<7)TF."WFM)+:>2%;686OSEXI_;0^)_B" MTN+/]F[]C/\`:*^+&NR,L>GZS\1_#,O[,_P]B`ED22[U/5/CA:^&/&[VZI#) M/;VVD?#V_GU"/R83<:7)=1W$7#[!4IJK+%5I55%T[VC5ERM_#"#IU*FKM=J\ MIV7,W;7\JJ\'97E&:4>(*_B7Q3BN*<)@ZV!H?5,'E_%D\%@JM9UZV"RC(L7D MG%&=X:BY1A2J5J>,Q&:8JG1A3QV88N4+KY[\0_\`!7:+X>>'-;\3?%C_`()_ M_P#!0_P%HWARW_M'Q!X@NO@/I\O@[0]*^SP2_;]3\8:QXJ\-Z/:6ZEW%Q+*W MV:VD1HI;Q9TGM;7\%/\`@I%_P4@\>?\`!2G^P/A)^SE$_BU%\&_!TT7B_7M M)/AV76_&_BG7I(5T^PU#Q1HO@9_%&GZ)X=\-2W%TNDP)KVIPW^H7:ZY?36%[ M9Z3::/\`LGXN_8`_;H_;LO[)/V]OVAO#?PT^"L%[;ZHO[./[-MA,UC=S6+M) MIR^(/%OB6"3S]0BE>&^>74(O'NEVMS:QS:#9^'=1,4NE_J;^SC^R;^S_`/LD M^"5\$_`_X?:1X1TQA#)K&LM#_:7BOQ)=122RK?\`BCQ/=I+J^LS1RW$[VXN[ M@V>E02&STNWT_3(+>TM\ITL9BTZ4ZCH8:5U-NG&.)G:SCR\DK4XMJ\FVI[Q< M-SYO-^$O%WQ-I8K(,PXCQO#7A_C,/&GC<;FN393@.+\Y4)RJ>RI99EE:=/+\ MOKKV4*ZS"K@,;4C"<:N7PIS=.?\`/+^P]^USXF_8S^!-I$_V>_^"8G[9?Q3 MUYRGB'XD>,]0\#^)/#]QXC^(5_:&!I+M=`^'?CLZ?X;2QTRTTW0+2-FFL=+L MBTMG5$WQ*\2:U+%`L26?C?^TS\`OV:_#3>+OC=\3O"'PYT MF)7^PQZUJ++KFL^4J"XL_#?A;3;:[\2^)[^)!-*VDZ#I&I7:I:3SO!''974E MG^/WQ(_X*$?MB_MDB3P3_P`$Q/@3XPTSPA M6_P_M/$]L^D73026\<;WLXUOQ!;37!CD\&:8(HM4MJJ+V"C1>,J\R4/9T,/2 MH^UJ>$9-9M;RVOK(6GC/3-=D2%KJ%;;3`)5[S_@F]_P1#G^/?A&X^-?[8,'Q M&\`^'=:O[6X^'_P_L)++PUXI\7Z+=6B7%SXL\4W%_I>HZ[I&B:O+-:+I&F_9 M]!\1745K-JLVH6>GSZ<'_3O]C'_@BI\./ACKEG\-P7X&YOQ/G[XS\7\3FF;X2ESRX:X,X@SG^W:F7T:L::=? M/:M"G0RV6*J>RI5YX#+*-+!.M;ZQ32A]67S7\`OV/OV:_P!F'2+?2O@?\'_! MO@*2*V-M<:[8Z;'J/C#4D=+82KK/CC6!>^+M;5WM8I-NJ:O<1!TC:.*,06RP M?2:($&%X'&``JA0%"X`55XXSSDY)`(4`!U%>FDHI1BHQC%648I1279))))=% MLNA_5&7Y;EV4X6E@-'\"IIT>I^$O&GBMM:.K+X1\9"X\E/!SV/]GMI]MY@OS=&_@C MLY`WP_X;_P""VLW@[4O#2_MA_L:?'O\`97\+>,;Z&U\/_$#4-/UOQ?X*NA+9 M+J23PZEJO@7X?WVKV+6!2ZF?PKI_B74(4L`N+C3\)XK#TY^SJ5%"7NMW MC/EBI\W*YS47"%^5_%):*^VI\!G7BAP/P[G5?(,ZSM9?F.%HX/$8MU\!F?U# M!T<>VL'4QN:T\'/*\'&NXS5-XK&44W"2W5C]XZ*_$S]H+_@J_P"/=.^/VH_L MY?L6_LV:O^UEXU\)^'[3Q+\0=6T75]1L/#GAVWO+?3[BWTW3;G3O#NJ6FL*( MM4TM[_Q!G?$_Q'7V3E M%^ZXJ;ES^XDYVB./B?X!\&_&__`()P_%+X9>#?B!E:K;?9;JQTS2M:UN>'2K3_`#HOVT_AP?A% M^V%^U+\,!9R6<7@+]HCXR>%K.%X6C']F:-\1=:LM(N(-VGV6ZTO-*@LKVRE% MG8(]I-#)':V<:K'9?U#]&7'PGCN*L+'G7M<)E>*A&I3J4Y/ZM7Q5*K[LXPE; M_:Z/O*\7>R:=S\L\3L_ROBO+0Z=X MZ^%7B_1/&GAN:YA,EG/?:)<6MTVEZA`L$)GTO6K>*?1=5M_,A\[3KZZ@#P-M MDL/]:;]E+]I#P+^UK^SM\(OVB?AP\J>%/BIX0TSQ#:Z?.Z3WNA:CYLNE^(O# M5_+!#%#-?>%_$>GZQX;U*>WACMS?Z5=O&L<2LL/A^/W"3RCB+#\1X6FU@<]I M4Z&)DN9J&;82DH.^BC%XS"QA5BU=U:U#%2D^:R?VO@]Q%'&9-6R*O43Q.4R= M3#PO%3G@*\[II:.?L,0W!R=Y15:%WRW:^BZ0@'J`?J,^G^`_(5^:7[*'_!0P M?M(?M/\`[3W[,GB#X6R_"OQ5^SW?36VF)J'BP:]?>-M.T7Q-JGACQ3XBEL1X M:T6'0M,L;I?"]SHZ0:CKHU2Q\3P7M:7K^I_##1_%_Q5;QQ+II\!ZK\2IH&M;>?P;'X'U1=3LM/T[4O#^HWMW< M^*=&=8=5O&9+:+36G;^?7B*$:?M75@J?.Z:ES;U$[>S2WY[ZC>R;/JJ_ MB7P3A\EPW$&)SJG1RG&9[/AFCB:N%QD&\[IXW$8"K@:M"6']O0E2Q.$Q"JU* M]*G1IT:;Q$ZBH.-1_L,((0`!#$`,8`C0`8V8P`.,>5%CT\M,?<7#EBC7&V-% MP,#:BC`PBX&!TVQQC'3"(.BKCX(_X*$_MSZ)^P9\%]"^*^H>$9OB!J7B/QYH M?@G1?!\.M-X>EU!K^QU'6M3OSJO]A:XMK#INBZ-J$Z-)8&*ZOGM-,::SDNQ= M6?H7B[]MG]GCX3^$_`WB'XZ_$OPK\%=8\;^#=`\80^!?'^O:5;>.--M]:LH9 M);:7P[ILUSJ=\NF7IN=.U'4-/L[C38;ZTNU-U'##(8$Z]).<93C%PC"4U/3E MC4OR.5]%S--)/5M.R/7K<8<,X7,U>ZMK?[4F]5FM_BUH\$MT+*/;;W!M(;:*^%O>O821*--L_,-?_9GU[QTC M6_Q`_:.^/^H:5.JK<^'/`WB?PW\'=)PP*W"6NL_"OPCX6^(\,-Q&(KB?"']H;X)_'W2+W6_@Q\4/!7Q,L-+>.+5I/!GB'3-XF&^"VUFRM;AM0T>XGBVRPP:M:V$TD+-)Y:>5.(/%K+_@HI^PS?W,-I;_M8 M?`8SSS>2@G^)/A6PA#$-Y?FW>HZG:VL"RL%2-IYH_P!XQC8*Z2"*ZE2FE%U) MTES.T;N$%)MK2.L8SO=>ZKW[;'%C<;P?['!U\?GN"^IYHIO`RQ7$K_LW,H0= M/VBP]&KF/U+'4X2G3/(;WXI>-O.MHX8XY!XS^)=UXL\3M)N@BN7N!JL=Q/>JU[=//UM;:W@MXEA@A@@BABAB1(T2**.)$2*-4BB141515CC4*%10/,O&? MQP^$?P\O_AWIGC;XC>$/#%[\6M=LO#/PUMM7UNSM+CQOK^HRV,&GZ1X:BE<' M5;R\GU*QAAAM#+(S7=OM4I(TD6A\4?BY\-/@IX1F\>?%CQOX;^'OA""\LM.F M\1>+-4M=%TJ._P!2=HK"S>\OY;>%+BZE5EBC=E)".S[$21T?N03=HP27O-*, M5IUE:R6F[=M-7W/3P5+AG):./CE]/)"?VX?V0_B3XAL?"?@3]I7X*>)_$VHW$ M5M9:#I?Q&\,OJM_<2LH6WTVQFNTGU.5L,ODV"SW.X-NBC5)6M^^_:3^-.G_L MZ_`3XM_'/4]._MFS^%W@/Q#XR715OAIS:[>Z19//I>@KJ!L[];`:YJ'V;2_M MYM+G[&;I;@6\VS;1S0Y>93BXVYFTT[124KNUWL[KJ^VQK1XBR+$9=C,UPN:Y M?C,MR^C6Q&+QF"Q=#&8>C2P]*=:M*4\+4K*].G"4G%>\[62;/;Z*_-K_`()N M?\%$M"_X*#>`O'GB6+P'#\,/%WP^\66^B:]X'B\9#QN;?0]6TFWOO#?B8:Q) MX6\&R_9==O;7Q-ID5HVCM);W/AVZ=[AUG$5KX[^W-_P5L\+?L;_M%_#;]GFR M^&J?$S5_%=GX=U/QSK'_``G/_")6_P`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`'&C!?V*/A8Y.S9^U'X, M4,L'RE\2_P!F3_@K/_P42\!?![X,_'?X:?L^?`CX)>!-2\*>,-(^(&A:K'J% M_JUM9^&KKP]I5_'I.F?$;XC^(+ZZC\,ZU?SP:/=6'@*SN+[48EU*_P!,2S\W MP[^TG_!2#]AV7]OSX*>%O@Y'\1$^%X\._$[2/B1_PDK^#X_&XG?2/"WC'PP- M&.BOXI$,J7B>+Y+QKY-8_<'3D@-G.;L7%E]O^%/#P\,^%/#/APS1W+^/^.,=GN-SS+^$,[R/A/`_5 MLHS+`X7#\2/+I9E+'X'-*<:>(S2&'PL_JKBJ4LO]O'$35.M5O-P_`+XP_P#! M/#]L/]EKXZ>*OVH_^"AQ_$WX,>.H;&:?QC-X7L-.26STB75 MM(;1-3B\3SZ-;:JT,NM^!]:T'5[C4X=`\40:1?C2M(Y"6;5_^"Y/[*QM)(++ M]G_]K3]E+XI6Z7B7-OK=[X.?Q/J.G365[;1RR6LFL:'H>ORZ5+>7%J\>M:[X M.U_PA%#+)JFGH9F^ZOC]^P_^VQXY^+OC?XB?!+_@HCXY^$/A;Q_J&CQ77PWD M^']MKWA_P?HMAHUOHLTGA`-XPM+:WU-[:QANKK['IWAZZUG5)C=WNNVRPV*Z M7QG@K_@D_P"+_@K^S]!\*OV>?VO_`(C?"CXGZO\`%(_%OXA_'*W\,6^JZ_XY MUZ'1)-%L=`U#3(O%6CW47@VWCFN+^71KOQ!J[ZIJ]U=7FKW%Y'TA[*JI2C*,J"]I>C.4FY2O*F[NZ5XMOP<7P3G2S;B#*\MX) MXIAP!F5+/:G$'#.+XEX=>5YUCL37IU\LS#@J"SB>-R+,*N/3S7%3Q=?+,-1Y M94U#V_L4_$_@#^WA^VE^SE^T]\-OV-/^"BGA3P[XBO\`XIW&GZ/\*_CKX$AT M>SM]?O\`4;PZ;IDVHQ:78:3H^KZ/J>L);:&T4'AGP#XF\.ZA+!=:OHM_IFH6 ME[9_RN_\''7P+E^$/_!3WXC>)X[%;+1OCSX#^&OQCTJ.W426R376CGX=Z_\` M,;=)8KJ[\5?#76]5N;>4+*C:B+E([2S>RAL_[$O@1_P2T^(5A^T3X!_:E_;" M_:G\2_M/?$KX665W;_#?1)?"ECX9$^$;S%U%8ZD(Y-4U6/49[1KN?5[-;#2 M/#8AUL6%[?'4IM*L)(/Q>_X.V/@7<3:'^R9^TI86)6WTK4O&?P0\57RQ*\,4 MNN6=KX\\`VHF$<;QA$\-_$N8C&7'ER+-`+X'#UJLH4LWP^ M-RSFK23JQA*C'&T:4W=PJ3EB<&J=*2=23]I"-Y5&^;:OD/&#\.L^7%']L>RR MWB"AC^&<-Q#B\MS7B7"9%*G0PTZ.%_C`8475?!J:AJ"V\>E:=\3=,MH#I M-D)TLIO'.DV&F:78#7/&-S*O\HRKC;\N,;/X,8Q]F_Z=EQC;_L8V?\L_+_T. MWIU[>Z5?6.J:9=W>FZGIES;7^FZC833V-_IVH6%\'QCP_CLCQKY(XB"GAL0H0G4PF,I7EAL534 MT[NG/2<%*#JT9U:+G&-23/S7AO/<5PYG&#S7"MMT)\M>BY.,,3AJGN5Z%1J] ME.#;C*TN2I&$^67+9_Z)O[3EAIO['?\`P6?_`&;/VA1-;>&?AY^U3X-U;X?_ M`!&U25I;'2Y_%5IIT?A.9KNXCMX+-;6*[?X-ZW'3K/A29_!WQ2M9TO MK^"+5;=_#/C_`,+7UD(#I$6G3W7[U_!/]CGP3$/V.-,_8[-Q'KOA:/X9>+/ MAUXCUQ]+M+&3Q))XZBU=_&&LG20]Y%8PZYJFOZQ?Q:7)J%Z;""XALOMD_DK* MG^:N><-YGDV;YGDF:48X>M@JN(C7A*5W];JT84XRIMM2E0<;XK#UD^6I3KPE M&Z<9+[7$>&N8<8YYQ32PU.C/PWS;!\2\6<.8A5J$I0XVXKR#`9)6H_4U6]I0 M_LG$T\YS*%2="%*&+S%2I-U::J3_`)^?B?\`%]_^"GO[0G_!.GX46\$WBCPS M\,_@/9_M)?M"Z'I,4=[:S^+H]%M=4\4^";R%;%_/^WW_`(*T;P?:&&SB>RB^ M)RO#'#.&MM,^NO\`@CQ\&_A+^TW\,/B;^UO\>?#/A#XW_M`?$/XR^--+\4ZY M\1="T_Q==^"-.TFR\-+IOA/1]/\`$&F7NGZ!;)IEW!=6,&EV]M#9Z#G M_9=.TR&RT[Z2_P"":W_!*/3?^"?GB?XE^+[_`.*\7Q?U_P`>Z%H'ABPO5^'\ M/@5/#VBZ;J=YJFL6WD?$AXO&J'7KR+P_*TA;3Q91:%`(X)9+M%TB?4/^"8' MC_X8?%+XA_$G]A[]L+QG^R3;?%O6KGQ)\0/`3:[?7%[>7=]X6 M\*>*K_2-.\.O-?7&*>-R:I7PM.EEV4Y+PSF6!K8_,*.48S$9=ALHQM9TJF84YTEQ'C*N&=. MO"5*I\B?M=_#7P%^QO\`\%(_^"?OCG]EO0-(^&7B/]H/Q_-\+?B_\,_AYI8T MKPUXD\!ZMXI\$Z1JGBF^\+Z-I<>E62V(X(DU+P MSJNIZ=^$_P`$_B+\-O!_[$WC3X9^-?V,_"GC3QQ\?/BMXF\&?"W]KOXAZ-H^ MD>&/AA>Z[X2\%Z#;:9I_Q,E\)W6NVFJ_#W5;'4/'*Z1#K^FZ5;6^KW6L7L9L MX=3MX/ZP?@1_P35N?!7Q\C_:J_:-_:%\:_M4?M`:5I$^B>$/$GB'PSX<\#>$ M/!%E-#?6Y;PIX%T4ZA9Z3=I;ZGJ<%I'9ZG:Z-8'5=6O;328=3O+:_P!-R/@+ M_P`$J?AY\-_V(_&O[%'Q9\6?\+D\-^+_`!%XH\5#QG;^%+7P7K&@Z[K%GI%O MHVL^'+&ZU[QFNGZYX;O-%MM4T[4)=2EMI9V6WN]-DT^2>P2?J4YUG4THTYJO M:"C&?(ZU+#QG&46G"*G*G48K-\ORW!<*87'OC M?&8/*,2LBS3"Y5+-+/%D/C7Q#X!_:0^&V@:GXFM)[BZTZZEM?% MOP@EBL](O+J"UN+G0]#MVAT70II1"_\`8^DV1:&R,'_$K^NO^"^0S_P3UUT; M<@?%?X7D\#"[-0OV5B"8\;75=I"$JVTA$QOCR_&__!(_XB^)_@O^RA\,=(_; M%\5Z1XJ_9+\;:OXU\`?$W7/A;HGBK6+!_/\`#]_X.T/1M,A\:^&UT_3?!%_X M:LGT4ZWJOBN9;7[)I7F0Z-8Z=8Z1%\5/^"6G[5GQY^$GC3X/?'?_`(*+^(?B MIX>\377A'5=&.I?L^>'-*B\*ZQX9U9]0FOH[;2_B;:76KR7]E-=Z6L+:II<% ML9H;T_:98K==/J=.LUB(1P\TJV%A",E.DTI*DTXMRJQGS)Z/FM=VLVFDO9S+ MAGC5Y+XE:AB9U*5.525'F/BI_P3O\`V+M<_P"";*_$*7X0^`?AOXWT M3]E#3OBM9?$_PMID/AC7]/\`'.D_"2R\3V^M:C>:9]@36K>]UN#S-6TK5'>' M48;BYCMWL;TV6HZ9\U?M#_M/>/?%?_!`;P'XM^)EWJ[_`!#^,!\-_!TZMJM3>^TU;C57\7_#SX67=W?WC;9[T:M<:R+ZZVO>V_U/=_ M\$A?CK\2/"'A[X0_M#?\%%/C%\2?@9X;@\/:9:_#?P?\/O#7PPM;O1O#D=M' MI>GZG>0^)/%MEK-KID6GZ>-)BUS0-2CL+RRL=1B@^U6UO-9_27[:'_!,[PO^ MU/\`";]G+X%>$_&MK\'?A-\`/$NCZK'X5L/!8\4CQ#HGAS0(_#&BZ#%._BWP MS'I,EMH9SHUFJLJ=#V,GA9TE#FHKVE6=O?DZ M524&H1NES/F5W:/,DF9AP7QCC,KXMQ&1<#QX1KYAX--_E;^RWX5M/^":O[<_[ M,^E>*)H?!_PR_:D_8>\)VWC;4+IDTOPM:?%SX>>"H=>\5ZCJ!@LH;(ZI!J/A MRV0W44*.3\0D>^,UU+?7L'Y__M"_#G5/VE_V9OVP?^"F>NVU[:3^-_VK_`NG M_"26[>[AUC1OA=X5AUWX?!XIUTU89[.:/Q#X`\+1J6T\6FN?#6[F6.&2"VMT M_IN_X*._\$[]*_X*"?#[X>>$I?'P^%/B+X>>)[C7M+\7#PE'XYB;2]7T>?3? M$/AV30SXD\(+)'J<]KH%[_:*ZC!)"VCQ0"VD%UYNG.\5?\$\-!UW_@G9;?L" M:=XR72K*#P7X7\.-\2)O"\%Y(_B/P_XRT;XA7_B__A$+37](0C6/%^F76J1: M-_PE*K:?:[>&:^G6%G3.>"J-5:7)#V$8UI44FG^]Q%/DM&%O=A2DISNGO4OK M9'FY[X.\38JAQ3PAA<"JW!>693Q-GW`TWC<'&6*XPSK(/?V2=+UK6-3O\`P!!)X;N+/QA8O<:/?Z;=E-0:VTMEN1Y,L1LO MOB7_`()"?&70/&_PJ^(GP<_;GUWX/^,_A9^S_P"#/V>XO$=K\$=)\7ZEKGAK MP=]JMTN4?5?B7:VVF6M_8#2K2/119W"Z3%I=NEAJ"Q?9[?3=+XP?\$I_VB/C MEI_[.^H^/OV\]8U7XN_LY_$;Q[\0O"/QDN_@/HDNI)-XEG^%>H>&-/M/#-C\ M3M,T[37\&ZW\,(M6M+][C5%U0ZR+6[L;:+3H=USHUY+%1C_#SCK&93QG1Q/!6;XG-\ZXDRO/()5O#.IE M&-P]+B3A;-<;@Z>/K8J'%#Q'L,OQZ5#'XZEDM7V/[R*=:E%^!_\`!7+]EC]G M+]E7]GWP;^T_^SQX'\&_L^?'+X3?%_X?7W@/Q)X`L;3PO/K-QJ5W:3 M&EM8ZXB0V[:\XBMEU6*R\/ZC;"YAT"76K.'\[_CA\8/B+\.OVA?^"O7Q$\%1 M:MX4\6Z[\'_A5I=_>Z--<:?J_@JS\>^+?@1H7B>\6ZCM+'5+&:RL=5U#24N8 M!:ZAIMY=66H%K*+3Y)=._;+1?^"3?B[X@?$'X?>.?VS_`-LCXK?M7V'PLU>W M\1^$_A]J'A?1OAWX`D\0:?<1S6-[J_AW3=?\1VU[$QMK8WR6AT:\U*"VL["_ MU&;2#/I">EZ3_P`$O_"-W^T5^V+\9OB-XUM?'?@K]L+P%-\/?$/PN'@Z/1+C MPEIMPGAF*34++QJOB+4FU+4+<^&HK[1[RV\-:!?Z/J#6=W9W:3Z=9O;DJ%64 MY5*=+ZO=\L5&<(SA:C7IQK)4VX*?/4A>S;22EHTV>MQ'X9<9<0YC5S'(>&X< M!X3'9E@X4_$?X3^!_%'C7QWXK\$>%/ M%VJ^--3\6>'--\0ZDXU?5=-U.>#0[6[U*YMM!TFPOC::18Q0Q1.;R*2X'SO_ M`,%@?BQX+_9!_8W\"_LJ_!N/0OA3;?'6^C^$^D1:6KV6F^!?A!IJ6;?$?6?L MUEYNH75A)_A]9ZC<&[F;PSK]U?V$6HW>)'?3O#]IJUQXXT. M\OO#=]+X3OIWO]+33=.E&C:A937:PZA/#9:UJ$-C;P37-O>:5\-_"S_@DQ^U MK\"[?QEI'P0_X*7Z_P#"OPGXV\?>(/B+JGA;1?V<-`U&W_X2+Q"EC8W5W)?Z MK\5;FYN)DTC2M*L4E06B/_9\4XMH))56TS]E7H3I\L'6ITYXB,%3]G!J%6-& M4?=G55HQ:G%>_I9),) M?"/P\\"^%O&?C*Y^(OB_PYX0\-:%XI\?7>F0:)<^-O$>DZ-96&M^+9]&MKF\ MM](F\1ZG;W6LRZ9!>7<.GR7K6D-S+##&Q[6O1_K7?YV;7W-^I_35&?3KGX47MMXK\17%H MBVEQYDEUX!M/%^EN=N5COY"DMO(BW5I^OU8_B+1-)\2^']=\.:]86VJZ%K^C M:GHFM:7>()+34M)U6RGL-1L+J,R1"2VO+.>:WG0RQAHI&4R)G7_!C&/LW_3LN,;?]C&W_EGY?^B" MKC;\N,;/X,8Q]F_Z=EQC;_L8V?\`+/R_]#^K?VI?V3_B/^SE^T?\;_@7)X0\ M;:K;_"GXH>,?!FEZW<>&=1>3Q!X>T37)K?PSXG\ZRTA;62+Q)X<@T[Q!%)"M MO&(KS"PVP@*67@G_``K?XAKU\!>,!L*!O^*8UKC;Y63QI"_*OV>3+#:J>2V3 M%Y7^A_Z6X7-\OQ>%PV+I8JC['%X>CB:+=2*;HUZ<:M)[]823?G?8_AJOE^,P M]:MAZF&KJI0JU*-1*C4LJE*;IS2]W5*:LG;6ZTU/HW]A7]LKXH?L'?M'^`OV M@_AA=73R^'=0MK/QIX0^WW&G:3\1O`-[-9#Q-X&UP0VS1M::K:0"73[VXL[H M>'O$-CHGB*TMQ?Z-:K:_ZFO[(?[6'PC_`&U/@/X'_:"^"VLSZKX.\:65P[6E M_;26.N^&-H:??3_ M`.1X?AM\1%!'_"!>+U*;5)/A?6B%($620-(3*I]GDW$%%7R6!:+RO]#_`&#_ M`."/G_!0[X[_`/!-/XZK+K_@CXF>)OV:/B/E_&7X=V/A[7IVTUC<:=!!\ M4/!=A-I]O91>.O#EI9R6EQ;^9:6GBWPVEWX?U*2WO;/P_K7A3\5\8.`,'Q?@ MO[:R:IAO]8\OI->SC4IP_M3`TU4G+"5.9\KQ5)RF MQ,8V+B6BDDELDO1)"Y8_RK[D1""`8Q#$,8QB->,;,8X[>6F/38F,;%PAM[<@ MJ8(2",8,:8Q\HQC'0!$`'8(@'W5Q-119=D%EV7W(15"@*H"JH`50,``<``#@ M`#@`<`<#BEHHIC"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** $*`/_V3\_ ` end GRAPHIC 5 g19662image001.jpg GRAPHIC begin 644 g19662image001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`L0%-`P$1``(1`0,1`?_$`.$``0`!`P4!`0`````` M```````)!P@*`0(%!@L#!`$!```'`0$```````````````$"!`4&!P@#"1`` M``8!`P(#``X&!@,*!Q$``0(#!`4&!P`1"!()(3$305$B%-05E=465I89.5EA M,G:WN`IQ@9%"(WDD)1>AL>%2,]-7EQ@:\/%B0V-U-W*2XE-SLS1DI$55)K9W M6"E)$0`!`P($`P4%!04&`@H#`0`!``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`R58&C-78#)HS#DOB!_`BO9[&?X4W#_P#9*]?O>R'HBECT1-$31$T1-$31 M$T1-$31$T1-$6SJ';<``?$0'W7M#M[6H,/].H$M:*DX*8%]:%I`[5J)A]H/_??_``=2>I'V MKTH.96[?;SU/QX*%.Q`$!#R'HBECT1-$31$T1-$31$T1-$6FX!YB`:A4`TYISIS6WK)_Q@_M]L=M1=Y?F MP4V5W8N,FIZ#K<3)3UBF8J!@X9DXDIB:FI!I%1,5'-""JZ?R4B^609L639(H MF455.4A"AN(@&IHFOFE$,(+YCP:`23X`8E>3Y(XXS+(0V(<230#Q)P457WM. M&\L9)EL)<&Z3>>;^4(=?WO9I3$R#:$P1CT5#&*#S(>>[4#.F1S9,^VR48$L] M<%W]!%4VP:S:YV!JNE6PO=SD:=`YHY8H=RVEQ/Z&WV MNN9#Q+?E!X5)/*M>[#BI#\0(YG"IMGFE&Q M4I8S?2*P+$0$H+.W"38JBH&%-%,FP:PZWG MMJ"G#2>"ZS8U;6FT3"IM:^Z?=1A5+87TDR:>G[`)JQ[1^N*@_I*(:![0>(5- M=_JVL_\`1MC>_L>:#[BJ"3=OY41!U#QN"L<7!(/U2Q>:W$$Y$-Q#D1[:JCD]RQY- M4T5#V+MY9REF2(B51[C7)&%[\*H;>)V\8G;(:<5#;R#WL4=>3I71C.YCW'L% M'?@K%=[WW+I8SWFW+Z5H-/\`TI$SL>>7*S#M-<.]45G>\3QSH#D6N<\7\J>/ MR@""+AWE+`-G9PS57<2]'QQ"*3;)8W5N&Y.K?;VMM2C4(VCSP2CV?O6/7_7C M:FC`?ZHT_5M/>33^=!3_`*RKMC/N>IK<&D(8@B/D&^D>KZ7<'+;W$;SW'\5?]-ZU=,]7F;;6NL6(G<:-:7Y7$]E" M`/'%7R0D]"6.-;S%?EXNMI*0T@TE(YT00`0.W>L5EVRQ1`0V$IAU6@M M=BT@CN6R;>YMKJ,36LK)83PGJ#IV)ZA-^GJ#?;?;?V-0((%3P3U(P_TR1ZG8M^H*=-$31$T1-$31$T1-$31$ MT1-$31$T1-$31$T1-$4>5V_%?XS?Y>7.7^)+MXZ(J4]C/\*;A_\`LE>OWO9# MT12QZ(FB)HB:(FB)HB:(FB+YJ"(!O['L^WJ+0TNJ?F4S17#FK!^?O<7X[=NC M$W^TG.2\VJO&X[QC6!;/+YD6=31.J#.%CEED2,8EH)2B^E')B,V)3EZS M&4,FF?)MH[-US?>H_P!-TJ/+#7SRNKE8!B23X`T'/G0&JQO<&Y-,VU:NNK^3 M-(!5K*XNQIA7O_<"<%BQX@9]Q;^8QR=.V#(]YL/&WMPU2X@RF:74'SMA$6A@ MT717<4*'<-V\>OEJZBU(*!; MC(X`ACN?:6CN%*X]Y6J;+_5?4.^_4W3C;;>:3Y14%PY4'`X<*X\#6BS#.-'% M7`_$/&4+B+COCJ!QK18=-,1CH9N!WTY(>F";B>M$XX%67LL^]$-U7;Q553;W M)>@@`4.>=7UO5M?NW7NK3NEE<32I-&@_E:*T#1V#VU6Z-+TZRTJW_3VD08T` M8\S3"I/,GGXJN4NW?.&RJ,;()Q;TZ0E;O5&"F\G2+*.J[G+&JB1=Q0C;'A)XLF81' M;I5D(?)+!J;:OL,4OP*M[OGX9OZYS!1\;\.)'#W MK#=3ZJLVT<^[=#U"UB!QD8!-&.\.\E17A@,%7C`G<-X=\E2IDQ+G2DRLFJL+ M3Z,3\B:F7$CL/$R!:O:DHJ77$GB`BDFH&_A^G4C=1@<\1U\]*_:M/-,*_!7F@IZG1XD$AB[AL;J$Q?;WV`#D'?;< M-PU6Y(I&UI\*+/VRF2CR]K0<1EQ!'C@N*GJS7K5&.(:RP<-9(AT'2YB)^-93 M46N0/[JS"208T?`5%#YD+L^<_^)3J1MW`W ME):K-7X]1=XSH25LD^#!XIAN`:M3M M'U"W>7V<[LA_+X>U:`U[H'U.V&UU_P!--:G=8L\P@<]P<3S-`:.)P',X*EV# MN^]RMX]VI]C;FIBAUD=:%7)'R!C0Z.+,O09B*^FHK(Q;A@A7K.4__FS`BQ(H M4.HBQP'?48M8N[9_IW["V'AF[_M7O5CV]]4.]MI78T/J3IYG9&*/<`6/%"/- MB#6@KQX]JR-.)G<`XQ*@#X:OMM>PW3/Y9J%U]LCJELS?\`8B;;]W&XT&:&0ALC2>5* ME7P:]%L1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4>5V_%?XS?Y>7.7 M^)+MXZ(J4]C/\*;A_P#LE>OWO9#T12QZ(FB)HB:(FB)HB:(O@8X%*83G$@;F M`3;_`*H;[`/Z`U`/HTO>*-"E#3*TM:2'5XA6`=QSN!8H[=/'F"7TFC0@B(^H=,I\LV9M#4]\Z MO'I^E-(96LK^3(N9_O5I3M\,18MP;@L-LZ4^[NG@W+11K2<2?[5A#<+N+O)? MO^('#AS[H&E:OU M&UXZS?DG36/).;%HXT#1XT`'`<>TGT.,9XSH>'Z'5<88TJ4+2*'1X5E7JO6( M!@VCHJ*B8Y`$$$&[5L4B8G$H=2BH[JK*F,8_%O,LB, M-CO/.-Y^PHJBDXJ9[$UA;FD[ZVEJKQ%I^HVU-Q`Y;-57<_CUCC;(!1%PRR?BIC$U M.U@[*13TC3!&L?\`%]D;%4$#"1VF8^_ZIRCXZI;G3[:[_F2M'K4H'^NC&QM\,+Y[=EKK19E;/"T,<*5+:TI6A)/(X\5!UD)OW1^S;-J3U:O^2U`IE)//AARHN:]4BZW]`KCU[.>76-F,Q=ZA<\-;S%#7(13`@_!3(\"N[ M1@'FPW;51TX;XCSD'^&MBFSS;5P,^5-%(YY"A3HHM&MD9J*''=L()R"``/6D M)=CC=K/4H;A@+O*_L6_^F77O:?4B,6K7?H]P.-!;.-'/('%KL/94>%5*X!B" M/2!MS;=7EOMM[?L:K"K185&BY!$#ICX"%%>VC+^`6\N+`:CNHM?;YZ9[6W_8/ MM=8AC9>'Y9VM;ZK2!@,_$CN)Y+"BYN=OWD/VX\H1$\UFK!*4->226Q?GZG`[ MKZJ+Y/\`Q$X696CG0N*G;6A0ZA3]0C9V0HG1,8`,0N-W%M-I?^77+R(P_L*^ M;W4GI7N_HQJ/ZV)\AT9TE8[J+,'U&(!(Q![14X\RII>V5WOU+Q-UG`',B8C8 MB>>(MH*CYT<+DCHRSRIE4&4;`Y&0.`MHNPR(G`$I8BA&CE7W*Q4CG`QKE9:C M^M\CB6NY&OW]_?[UT=T3^I.;5)HML=0',;=8-9WM[>*F0R3R??\ M9LHU6&SRLV3P)E26"OT+/2(^]8FB7=\HF6'QYEU,B:K6.;V+U1^)["!D62AR M>]W8$6$BBMZ+FVT8,IK7F?N_>NE]9W?+M75H6Z^U@VY>FD=RWY8G?E;)_?%2 M'`\E?(@LFOT*HK%6161*JFB*6/1$T1-$31$T1-$31%U MBX6:O4JK62XVZ680%5JL)*6*QSLFJ5".AX.&9+2,I)OE3`)4VS)FW.HSQV%N"^:5X;0<<3@/::!4\T[+2*2ZE.2)C"2?8O,7YZXK4$$546D-5968!(EFE4U03%.3L:+;XZF7)Q_T=NF"0;$0# M?NW:.A:9TNVB[4+FAE]'U)2?+5^7!M<<`>'@.UY3#7&F[-RZCNS7YM>U!Q]:1V4#DV,?*P=F4`8\ M\?9U-HFEV^A::S3;1H;1HS$#B>?Q5Y)2"'F;J\?/IV\/:\]8Z2:U_+V*XL:Y MK2U[BZJU`@!J;,HAM.;O>MITBJ"&XB`!MX`(AX@/4!O`0\0'RU(6M=Q&*F;4 M.SU-:4XX>Y66L5CYAQ=$NK>1J5O$9-K0?1C)<$HD<%&B\?;8WTG M:Y6BP`4MO'.,I\KNT<0M=[MZ5[,WJUSM8M(FWSJ$7$30R=I M:B4I`30.84PM$TE[8"K7"2$^RA'A4X_%3:@R4R\CAF[%/3Q+YCX4YFXU;9(PS8"R+9L+ M=A:ZU(=#2UT:P*(%64@K1$"(K,EP#INZ2#U$CF+OM=+*YCO8O4C./,? M>NF]C[^V]U!TF/5=N2MD8YE7MK0QNI\IXUH<*JZ?[EQ$S7XNP1,G!S;)G+0TPR<1LK%R35) M\PDHQXB9N]CY!JY!1%VT=H*'*H0Y1*8IA#;4Y+7#*]HUPJ"PX.;CVC"O)867=Q[9KCA?=H+D;QO:3\9@^6G6CI=.*?.1>8.R(= M^16%3B90J@R4?4Y)8H&CG)E.I@[`&H&Z#HAK%=8@,7\RV&4?=^[L]W)?.7KQ MTZ5(\IHM7C]R`F&0\ M@:E%'>UFRK;-%,O5&/2`CUZZ3(4&B=U@"D(9ZFB!??3S M\'<^SV+9#XQF,?6!)Q9,37*033$;325EO>YVSX4O\#Z05URH+-\0`*<0*FKL M!%BZPZZMG6+R8_DY=Z^2O5SII?=+=Y26%'LT5[BZUD/Y@#@:\B,*@$T/!238 M+[C5)S%VT^4/%/EW/IRUMHN(W"&$9>:.JO,9"1(HU94F`]\J"(O;;2;6#`"& M`156C!]0^_HJ'&HBOG7>E/@G(#VDX\:BN`X<1VUX!;JVAU?L-Q=&];VEONYS MW]I"TP$N.=]'5;DY&>NIB9QO8[-BAC. MO/6.]F:[4CL/H^=VZ6$1?N8J.>$8G6\1,+?Q'JZM7C1Y'2Z>W./-6E>[[%=- M_3=N/4]S=,K2?5GE\T),4;C^:)N#:]I``%3R4DD_F6EU&YUZBV]Z-7F+DX*P MI#N:`K*!N$R9%1P:MPDXH;W@>U%;HG4+&JF3=N$B&.@14I3"6Z!A)]JW+=:Y MIEEJ#=/NY#&]_P`KG"C".B*E/8S_"FX?_LE>OWO9#T12QZ(FB)HB:(FB)HB M;AJ#G!OS8(L7'^9ZYNO\*<9:KQ,H/'IV!5JBY(.Y3].@>SVZ]N)^N7+,UI:<">'J'A\.'>?!:FZ MM[D&E:.S2HWY;BYX_P!WQ\1C7L4=7\JQPU:V[*&9N:]LAT';+%"">(<2*.4E MC@A=K,P)(7JRL"G+Z`+Q=1=-V*9A$RA/C%0`$-]9M]0^Y)X&0[9A.1[_`#RM M!Q#6FC0:?Q5!IV!8ST;T&WEN)=;F(>V(96&F!<14\>SAA3BLYTA1`0\!#8.G M^H`V#^W;7*A)#A&`2T#CWK?30YSS*[`DG#N7VU,O5<9\=1'QB$0,FP+*BF*I M8T[I$C]1(`$153:&."ZJ0;#N8I1*&WGJ-"O%MQ`YYC#FYP:4JN0!1,1$`.41 M#S`!\0]O?VMM*%>]#2O)#&+L'D(CX@&X>/Z0_HU#'EQ4A)RU:*KHV0L=TO*= M-LF/<@5R+M=+M\2O#6.ORZ!'4?)Q[@.DZ"R1@$2J%VZDU"B!TE"E.00,`"$O MI!XH_AX=JMVLZ-I^Y-*DT36(FS:;*VCF'&H6%+)NLF=D7N-N&,9+3,M@^Q.& M M>'<3]CW+YVWKM>^F[JM'%9EQVK>/SAGY70EY#CA@,M'#'&HY46;K5;%$6RN0 MEJ@7R,E!66*CIZ%D4%`41?14NS0?Q[M(P"("1=JN4W]>LN#Q*T/;\I"^C-E> MVE_9Q:C:.K;W$;9&^#@%SXB`AX>/Z`]G]&AJ."J2YI&&*IEES%-*S;CBZXHR M'"H3=-OE>?UR>CW*8&*JR?I"7WPV,(&])^Q<`1=NH&QDETB'*(&*`A(86R-\ M]#4*V:[H.F[CT6;0=38)-.N6D/:>50O.NND1E?@+RWFX:$E5X_)G'+*P?$F9`R[7WZJJDS!=(7*[5--P[;,CJ![Z6:I M'_P3NTVIC&3+^J8P`&^PCK$7.(#3#4QEQ!/MYKYQV%M`^[C9)5ML7M$A/`MJ M`XGG0&@-<<5Z5'#_`!7B?#/'#$E&PFW%'&K>D04U`.UC>K(SGTF9(SSNRS+G MQ%S,6!R^,Y<&W'90XE+L4I0#8ELV%MLQMO\`*![U]I=B:/H6B;'TVQT(-_I8 MM&.8]O!X>UKBX4I\V!X<*+G>2.!*?R5Q!<\2W!N8&]ACO6@IML=5M,T^X1A% M'52N==DVITG\1/5F9*FY;N&ZB:Q1()0,`&'?V<'9",,055[IV];;IT*32[QM M(7,)C(-'B0"K'`]SJ'P46G:(YY7G,ZF1^(?)"44D>1W'1Y-Q3BVO#I`XR/5J M[85:PZD7H`DB8UGKD@DF@\4V'WXW42<;`<5MK'IMT^=Y@DKZ[1C7F!]O:M)] M"NI%]N$W?3[]D/1%+'HB:(FB)HB:(@^6H.=E&;L1;#&```/9,/2 M7^D0$0WV\0#PU+03-4<:KRU^];RC4Y4]QKD7=F$@+^HX[GAPMCXR"QE685C% MJB\,_?L]S"4J4U9RR#S<@@!Q6`?'PU]`.E&W6[=V'8F/_P!Y=!LSSSRN!?QX MX`@>Q<=]2-8?K&[IF28V]N\Q-'>TY:>\$GQ6=SV+L&H8'[7W%^'.S49SN0JF MXS/:?63(FNM,Y2?N+,W%0"`&Y6U?<,6Z>_B"*)`]C7(G5777[@W_`*C='Y(Y M1&WPC&7[P3[5TAL'2F:1M:VMV_YCVE[NVKC4?"BERUKU9FFB+I]KI%3O4<:* MM4)'S;'K,=--\W`RK5?Q`'+!V0R;Q@[*'DJBH10/;UZ5+5;[JSLM4B]*\9GI M4`\".(P[*TYZ,366FF2HD]R!>D-4UP)2YI:3EISQQ^]8J=$W!I*OF>!7;)E M#_3PI3GZ*9(8I"'B*1F"J@>11.(:\HS/'YGM))[#A^U66?>6ZM*G]/<>WKCT MA4^M:/;=,`Y5]00O%3V`TKBN6;]SKANU4]Y77(5EQ!)@8I1C M&WJ6VGL&1Q`P#XE6$H[>`^SJ9T[0:EWL-0/'Q4,'?@O'%[D5Q^Q7EC$.:\19%O>,;^$*K$4^]5B:L;ND7QDHWE"K0C21 M6F#MXV=8,W`[H@"13'$P`&^K5JC[:YC$F8$L=]X]^%.Q!4C'9DY"UZY]OO#\?BMTNUS28AGN+NU;%VF5OL5/ICEEQL[ M8N8Y_7MQZF0X5!(]]*U5WW;H[Q%'XG\.:E@J9Q+EO,N1JI;[JG"0U&CTPC$* MO.2OQ_%(+3;DKGI6;OI-T04$D5#I(@00`0'8*FPU">VMQ%)&Y[ZDBG#PQ"VG MT:^H32]I=/8M"U&SU"]UF":01MB8"ST\K,@SEU:US5`8?BKH'_=-[IF;EQ:\ M:^W).59DZ*)6DYD&N7:<73*;P3>D?31,<5E#I$P;@?WP0`]G52_5-3>T?I[= MU2>_]BS1_6SK-N%U-H[3?"'?+*^IJ.=06`?'DN''@QWE>:*JSOE5RD0X[4]V MHFFOC^C2YQ3K7S(!^%%) M_MI]0'4)WK[OUINE63L?3A+JT/$9&%H'O\5>%Q[[#W#/"SKZ27Q.S<@KGZ#D MWOS(WQ>C4$GCAN=,7K:BQJ(1J[E(YNM([]9^HF<`-U"(`.KG%ID#8O3X^/VY M>*S/;_TR=.MNP/=>QS:E?B-U'S&H!H>#:FE#C@:=RPD[?$MX&XW"`2.95M`6 M^TP:!U!`PF:P\[(1C;JVV((>]T"AL4`+MY``:Q&6$P5C';]Z^9VZ+9VG[@OK M:W9Z<$=R]@:.0S5I[1EU%5GL349.HG66$YCK-ZE9IJ" MCS@<_NCD)',TB%\_`NLRL'$VK3V+ZS]"]5?K72O2+B7A';"$]_IT:/@U2`7. MZ57'E9G[M=)N/KE3J<.\G;#.RKE)G&Q,4P147=/'3A4P%*5-)(=@\SFV*7<1 M`-5V.4U6SM0N['2K"35]0E$=C`QSB3RRBOO[`L,WM>7.4S]WF;3FZF1CUA6+ M--\@\AS(`4Y4H^CV(D@SBB2NY$A*:0>/6)0(&+Z:''5Y"S&H*^> M71&]U#X=(J-,GEN9G$7$M^"S74A$4RB([[AOOMMN`^(>&X M^QK)7<2OHZ'M>,[/E.(7TU!131$T1-$31$T1-$31$T1-$31%'E=OQ7^,W^7E MSE_B2[>.B*E/8S_"FX?_`+)7K][V0]$4L>B)HB:(FB)HBT-Y#MI0'`\%`UIA MQ5L/,S,Y>.G%+D3G([D6RN+\-WZVQJ@"<#?'L?7G@5Y,@D$!!1Q.*()E\?UC M!J[[:TXZKK5II\0#G2W+?*>!;6I![LJM.N7;K#2[N]S%K60&A'%II0$=X*\A MJ0=2$F9\^?N%%Y:54>/'[LP]2KB2D%CN'2YS>R=9VN8PC[8[Z^CYB%C9"U@` MCBAMG-:UN`:&LH`T#@!P`"X?]>2\U02S.=(9)PXEQJ7$G$DGB3Q)YE>Q!QXK M;>FX%PI46:94FE7Q%C.O-$R%`I2-X6E0D:D0`#P]R#;7S7U60S:O=S$DYKB0 MU/$U<2NZ=-:&64+0*4AC_P"B%635"JY-$7'D=-EC'%)=NJ1)51`_I'(IZ3E/ M_E$5!((]"I/,Q1\0]D->@(ISJO'(Z689\I:.`_,OU)E3-[L`(8V_B8`#SVW_ M`*O`=2N)X8T52YS_`)34-[%]`(0-MBE\/+P#PVU*0"*'@I`2!0<%^5]'1\FV M5923%G(LUR"FLT?-D7;98A@V,15!P11)0I@\P$!`=2Y&4H0**22*.44E:UP[ MP#]ZQ1_YA)CQYQ77L-4''^(\65;+=VL4KD2RVRMTBMPML2HE<9*PZ#1::CF# M=Z#">L,C[M(Y^E7WB/GL.K%JL=LX"*-C`7<:`#`\\%PM]5[-I[?T:RV[I.GV M,.LWKW.?)'"P2-BS5!S-&;S/+QQY55Z7`+M%\4)7A]A:;Y)<>ZU(#JOL]-LXX!GAB+SC4 MM!)^P6T.E?0[97^@M/N=SZ9#/K=Q%ZLA>VI&;!K>(_*`>'$E7;&[-_;5,<#C MQ1IHF#R#Z29!`G](E"V=(CJI_0Z?_P!Q#7^Z%L,=$>E0.&D04I_"/Q7-Q?:1 M[<<0<1;<3,;*"']U\:QRB>X^6Y)*P.0'R]K4#86#O^PA_P`(_!31=%NE\4F9 MVA6X\Q7%5RB.8FC0S>'BY"V1[/X MTMCYZ#0^[N4;2,L#,RQM_Q\=L`_B22N[_ILV MT[0>EMI)T`9,!W]ZF+$`,&P@`A[0AN']FJY;_``2. M"TZ2@'D```#MX!X![.WM>&HU*<51;D%EF#P=A'*>8;$[2:0V.Z)9K4Y754!, M#KQD4Y5CV*1C"`"YD)`4D$B_WE%"A[.I9)6LA>\&E!]C[UCN[]9M]O[8U'5Y MWY&P6SZ'_BH0/;6B\RY=Y)6"3>2CE-1W+S8ZP@R&8_P`3RY?%2Y-UK.K.;;YY;F[N,Q`-35Q.)[S4X^*S MV\-Y/P3VO>"O'JD2O/KQL4=857;@-@=O1,8/ M<$2U<]/M'VAS._SCQ/'V577W0KI%;=,MMQW-X&NW/=14E-!6-IQ,0=_#@"1P MJ!V*6HH`!0````#R`/`-O8V_1J['BMYL;D8&@``QG^%-P_\`V2O7[WLAZ(I8]$31 M$T1-$31%M./241VW_P!SS';].I7&C25$#,:*"/\`F.\EN,>=JO,4:U<*-W&3 M[EBS&`"D?H,JTF+BQFI),P_K>B>.KRH*`'F3?ER^PU:X)RI"DN8.HA%B*'+[:9%BJ'\ M_9$A1UW7J)SB9X_-%(1[0<%R!9@,OHP3@',-?.<@V+#&52H`$9>ZRBWEHQVJAU^]6EXH MH('#A]O>L=U;1KR^MW3Z=<&TUD5R2@9Q M2N`[ M_3SXUCN!Z3Q0=A);_P`RKAGCDWB#CGB2R9KR3;(ME1ZXQ.X!RP>M7[V??G*8 M&$!6FB"HFF)R36`"(H)B)AW$QMB%,8/26:""OK.RT"NNY=[[?VMHP,P@Y?U5F$S%59<[J MIX71FE:!&'88\N7+VGNP7%VR MMIZWUZZ@OZ@;B:ZWVM#.,D;JO#H6&HB:7<&NQ)-,,QP*S#&A2-T2($`B:28% M(@F0H)IIHD*4B:::9`Z4TTREZ2E#P``#61R/9&0TC&G(+OIOHBD;`&1-`#0T MFF4``< M0.'?_9]N*USU1Z@:=T[VM)K5XXF]H1%$'4]1U,,>(`YD-/Q6##PZXUY'[@/* MR(I+MS(R1[18G^1,V7EWZZ@1536F`D[9+/EDB$VD)Y58S1@F)P%1=<``>E,P MABUC#+=W'\P4%:E?,SISL[6.JN_Q:O,E9)1)-*&YP`"2222*FA[>(':O13JL M!"U"MP54K<:U"'_`,,NYRD2 M?R*2JAP_XH!U:II)86?F:1XJR:GNO;.C1F;4[^UCC;_X@)]W%8M/>@[HV+,^ MX^A.,G&:\'M]6E)TLUF&XQ;9^PA9-I7U15@*3&.)%HV++-',QTOGBZ`'1$C= M),!,(F`+#J5[%%&;:-V8N.)X>`_%<1_4KUJTC<6@MVQM&7U;=\F>>0.(X5`; ME''B34D8@8EFE MWE>(_+4<,:\JTX>"G*Q3V,N;7)6U)Y)YB9>&A%EE6[N4-%3E=J M-@+[]^C5>,<5!*"1WQRH&,.Z("`%UX=E%.''%=5:#]-74'?5ZW M5>IVHF"$Q5#0#,\FHHS*YS,@I7S`DB@&4U62YQ0X(<:N&U?",PK0&,;.NFR; M>P7^9*6:OMF,GOZAI.R/2G=HM%3CO[U;>@U+L&Q/#?5[AM(8&Y6##XKL#8G3 M'9_3RR%KMZU8V>E'3.`,KNVKJ5IW*\3HV```0``#;Q*`C_;_`$:JC0\1BM@& MIQ_/7CV+<4.D-M]_$?8V\!'?;;]&BB37%;M%!-$31$T1-$31$T1-$31$T1-$ M4>5V_%?XS?Y>7.7^)+MXZ(J4]C/\*;A_^R5Z_>]D/1%+'HB:(FB)HB:(M#>0 M^SJ#AF%%`D@5'%8LG\V#8U(_A+@&LD,(%LG)F+=K`4XE,8M>QW=UR%V`0`W^ M,_+Y^SMK?WTZPQR;ONYN+VVAIXYFA:@ZQR.BVU"W@#+C[E@*'3%1/TCC_P`H MFHF)O$?$Y1+OMMOYCKKZCI(X'$>4YFN/8:$4*Y>8X`ND;B\.:1X`A>LYVQLK MM\W=OKA]DE!5-92;P'CQA(G34]4/CNKP;>ISI3&$1,"@2\(MU`/B`CKYV;WL M7Z=O#4K9[2VET\BO87$@^!!%%W!M2X%SMRSEK4F!H/B!0CX*^O6+K(4T1?G, M/5X;EW$1`-]P]D=]_#8=7AKRD?`QP+R`>_!4][<6-C;&6ZF;%`,27.IA MX5Q"A@Y=YWXD<@F:L,PE_+]7K),!+SW)3);W!C*8>OI>GX#Q- M(J7Z)QRZMAZ7T=ZH;/A$&S]TN-BP>6&XB.7#E\T@'^%?GL;'^8%I*YDH*:XE9 M=9ICTE>)Q455G+D"^`*&;R*D$5,Y]OU>L=O;UY..N<(G,6 MLN=$N8AP(:`ZG81Z35:7R([B7>3XDUYI8\_8OXMT^,?.4FD7_K2"F)J;7,8` M4)#UR#R6XF)(B)`$RITD/31)[HQ@\AI)[O5+=F>[R"&O'[!:]W?U>Z\=/K0W MVZ+;3Q`'M;AEQ+S0'`5IWT40^3LC\\.[CE5K)-,>RN3IB@UP6#&JXWB'$1C^ ME,C*BN\D%G$Q*J1#*>FEE0$ZB[GWRN4A$RD$A`VMTK[^_(=`USFM[*4_8N=M MPZSU1^H35V3Q6EQR)SP*4H7&I`%2<*_M5P4WB?^8TR M>((R]Y2Q^U7,(G4KN0,64\$"*>8":J'=R103WW]SX_IU.+?6;S^<]WI\LN:G MMH%EEQH7U7ZU+_,O/TK:!IRR^F/[U&=M>/9TYZ.&PKCNXC MWE^RM=W0)F#Q3.9O)0T6W/(V-[?,SUYY/^4BGM)4=O/;@3QCX.PH0-GY-V7._)F=0`\9C6KPT! M`1]205(41M.1I5XZMMS!5P7@%0G;B\,42(()',#85`57Z2%$#4,.FNO9P\5 M]/#'DL-Z4=&=;ZG:NRX9#-!MK/5\Y`R<1AQJ21P%.7)9[O'[`^->->)Z?A_$ M]>2@JE3(E"*:`*2`RLJNF`G?34Z^332/)SDL\.HX=+G\3K*&$-@V`,QMX6VS M!`T>4<_Q7U/VQM32-H:1#H>C1MBM8&T!R@%Q.)<2.)<<<56@I0WW$NWAL&X! MO_N;^WJH)Y+(B!GS4&:G%?7R\`U*B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(H M\KM^*_QF_P`O+G+_`!)=O'1%2GL9_A3H)1-N(;`(CX^`"(:[`)].)L?,.S>_\`M7+@ M\CRWM:#^U>@;_*S6N+.N^BC3=V1WX.%["7T_N.RD^VH76/2'5':AMIT)Q%O( M&U\17[PLG36DEM9-$7!R\(C+H&;K/9-HF8#%-\6OE8Y4Q3[]0"X;`"Y=P'S* M8I@]@=]3!4UU;PW;,DY<&]QHJ(Q_%;`+&<W;LV+9JR9-2%30:M&Z;9J@4H"4I&[5`I$42``[`4H`&I`R(',WY_ M@K_%''"P1VK?3@`H&@`#X?@OT+*$1`QCG*4@=1SG4$.A,H`)AZC',!"`4/;$ M`VU[-J5"28,!+Y61@=O+Q5D69^Y!PEP"JM&Y"Y#4(;.W6.A]"*E+A?KNL]*8 M`]X$K-0++R:3LPB`%(L1+ZH;%VD/3U2_:ZX-:1L! MG>X]@RY@.ZI'L4>F3NX7SSY!+FK/;\X3Y*C8&41%$F<^15:^A#-(5A,FG(5^ MK61_&QX,"D'K3YMX1 MU)4Z@2OK`H@5,@DC)"[.F#0D0Q2V$@LH-FW1*`^X6#V?)ND&:03WC\P_A!P/ M?[/!6'2OIIU_=5\-P=7]3?G&`UM M5U)M[;6C[8L&Z9H=M%!;L`%6@`G"E20*D^*JX><0B3Q M*@U265-[!1U*^>&$?S7958-=W+H6UX':AN"[AM+(-XN-'&E>7$CP6.=R;[UF M7\_6MU@?MD8RM=PF7CK1=:A)<$0Z=4S]O=SIS[%R9O'ZA]R;IO)-M]'K&2YN'8?JZ?D&#@T4- M*DM-:U%."Z1P]["U\R%..W]-;IFB0 M,@MF<`T``+OA0V#_`'1_I'SUZDU*O`+B!FXT6[4%%-$31$T1-$31$T1-$31$ MT1-$31$T1-$31%'E=OQ7^,W^7ESE_B2[>.B*E/8S_"FX?_LE>OWO9#T12QZ( MFB)HB:(FB(.I7'*VJ+%2_FQX55UPWXWV$HF]&#Y+I,5]BB)=IS&US`G4(`/3 MN,<(?U[:WY].\HCWE<,X`VIP[<6E:=ZTQD[=A`Y2_L6!-U"/LB`>/AOY;_\` M`.NS&AKF@D#$+E^@KCQ4_?\`+@H3R`%#S'6DNN^VVZQM9NI1,:;RS=4.IYQ'B7- M!&.4\2.%0MN=(==&EZT[3I'$6UQRKY_DNIL&^3C4K[:F1-$6FP>T&H$`\0"E2N&E85O+)&0< MJR2:9B])OB^5?Q9S`(^.RL>NW73$/;*8!T#6@UI0J26,31F-[GM:>;20?>,5 M0FQ\4,%7%8KBYTIQ=N@QCE:W2XW>UQQ3'WZO]6S]CD8X2FW\0]';Q\M>N<4I M3!6"3:NCW$A?>!TH/\9<[[RNST[CAQ\Q[L-%P=B.H*=9516KN.ZG$N#*E_55 M.Y9Q*+A14!_O&,)OTZIA!"#4,;4]P4FG[-VCI$AETO3+"WE)J71P1-<2>))# M:U/$FN)XJITO,0T`W*YEY!A%,PV("[YRFT0`0\B%,?8FX`'D&O9C&-;0`#V! M7^26"$?S7EF'`5I14:M/(W%%;9.'C>3G;BNW*(GC<;4^S9#E3&#?<`9U2)DC M%4$?8,8HZD>1&,P\,!7[E8[C<>D69SN?(_E1K7$_L*IJXY)Y7L;+WUB;B9EZ MU%4Z?>[S(\G3\)1YR&(`^HNWMTL]MJ90,/B'Q0)A`?+YL8\27%6YY.I7=BS8G[RK.4N-_#NLKE,FX^BK2R9R MR0HBH(#UA/SU?JUEZ M):$4)A+YY?$.=$T--.QPHJ/TOLFX?L<_]/>7^9\Q\R;V#DCHCK(EHG(&M,S] M("NV:0D3.+NCLA.(]*8NB)E+X%(4`VU`:30PR/!:/-V<>&%%*IB+`^',$PQ*WA[%E'QK"$2%)1M4:] M'12CP>H!$\@^00+(22IQ#J$[A14YA\1,(Z]H;:*`YHFL;W`46Z-"VQMS:X_2 M;=T^VL[>G&*-C*^.45->\\E5\$DP\B$#;VB@'E_5JHS$XDK(RXN-2:E;M@]H M/[-0J5"I6NB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*/*[?BO\9O\O+G M+_$EV\=$5*>QG^%-P_\`V2O7[WLAZ(I83"(![DO4/L!Y:B`"<<`HM`)H30+8 M*GAY!U>R`B.P?U[:B6\QP4GJ19RTGAW+=U&W'QL.XC_5L&O*K^S%1;F+ MB'4#>6*T$X@&^P!_2/G_`$:B,Y-**)HT5=7V+;ZHB/@7J]OI$?#R]L`U.&N_ M-0*5KV2'R$91QK4'[EH*AA`0$H;B'@&X[_U^Y\-'QYFT!1\C6X1^9WN"Q[_Y MFFB'MW:]LT\B43J8XS)B2YG-TB8$6+F8=U%ZJ<0#_#(1.SAN/C[0^>ML]$;U M^G[]#(P]RY*>"'$&E03PX>Q=AJ=FGZ59:Y]E>.T^\COFG&-P/CCW8KUH.!7*^`YL<3<(\D:^#5`^0Z@S7M,2V<).#5N] M17J1%TKCD$3']!:,L+)<"D/L;T!(8?U@U\WMT:*_;NOW6C2`Y8I#D)%,S":M M=[13M7;NW=4&LZ-!J;*%TC0'`&N4@8XTQJ?O5X74/2(@7Q\?#?\`X-6*@K3D MK]09J7CX^(>W_8.I26BN.*@:`TYIU#OML'EN'CX_[VVVI07'@,%* M7#@/FY+35U?%?,`-MU`4`-YCXB.VW](>.^O M4TX&'M`*`@7V3&']`[;>6WCL'CJ!<2*'@H9&$4+6> MX+4R(&*!=P`/_#:@=R`40'?J$0V\AW'^OSU$F MH4P:!VU[RMVH**:(M@GV$0\/``$=Q\M_ZM0H^O#!2YLSLC<7CBG7X>0#X;^` M^'^]J(S9J$4".<6C_C`Q"TZC;A[D-A\QW\@'R\-M34';BH%SB6E@JT\>Y:>H M/A[GS$?9\@`1V'R]G4K@X<*%0#W%H<1@74]F.*^A1W`!]O\`KU`5IYA0KU(H M:+745!-$31$T1-$31$T1-$31$T1-$4>5V_%?XS?Y>7.7^)+MXZ(J4]C/\*;A M_P#LE>OWO9#T1?F[N'//*W`C&6(KMBFNT>R2-^R))5"7;7EM+N&3:/:U>0FT MG3$(>4BUBO`=,RE'K,<@D,/AOMJ@OKUUF&D-#LU?A3\5H/KUU3UGI;I-EJ&D M0Q3?J'RM=GY%@C+*>.9WN46U?[U_<9B:FURA>N"3.>Q0I#HV4UV@:OEFLUQ2 MM+I`Z).M[4Y;6.#^+A:#U^N;_!`/$3`&J9NJ7A;F]`B,CCW=HJ5J#3/J-ZHM ML(M6U#;3Y-'D&8R,%`6?Q#N["<%*EA#N[\9++*Q(9/O]E]0D53H&MSQG+ENH?U6ZBK]N[=,$ MTE3#U]1-@J[:_F$,LEXPM+*>T_'Q*VIIG6;=>D[0U+7>H>D?H+RP=&QI=2DK MY`XD85X%M33"A5BV/>Y?WGN3[%[E'CGQCITEBYK*K-FJ473?C.,O'"GLJ:K5VE=8/J$W MOFU39VC1OT0.J,(QF'(!TA!Q&/&O)7+9=R+R=Y]=IGN!5ODGQN7P=>:=CBW, MX1#U91BWNMBQPQ:9"7>15;G4AEX-.-D(!)OZ@K.6[@51])4P`;;9?3O69=/W M;IUU6D_H]0MS1M:>8M.-..(IR[N MU>=,0Y5"E4(/44Y2G*/EN4P`8!_L'7TFF<'2N<.!<3\5SRX$.((H0>'8OH4P ME'[+!E3``R:E,&5#6O/;YLHPJ?,5OGH[N=L4K]OWCP/4/\JOYB,:#LP#N MS@.U9T;L[GT5A9%(HL**@MRG,)$CK]`BD0ZA0,*:9C[;FV-X;^&N3XWLD`># M5OV"Z#NO4=;/;!C<`8#A\5`IP-[KV9>1W.&_\66VJ1M@U2U&9S1R9A1W>"JP]UCGO8>!F%Z1=Z M'%5>QWZ\Y$CZU"P%L"2-%.8".9N9>VO%`BW31VBHW9))(IJ@(E(JX)N!O+35 M;L6,8>XT/9X8E9#ULZINZ6Z%;ZA;Q"6ZN)2QK3SH`X_`@_O5Q_'3DL.0^*F, M^2FQ2Y8I$BBY*54I3%!<"^(A MXW%LT9C;+4`%H/A7AQ65;4W:[4MFV.Z-RAEA).,U)'!HRUP.)YC$`XT7%07< M:X(V";"M1'+'![J8,X*T1;*7J)9I.7!Q`I$6;Y\JV8/#J&'8OI*GZA\M]>#K MRVS8O`7A;=7.FU[>.L[?6+-UR#B"7"GMV,O,E069&BI=484`Q5OPM#E+L[,HX^8?BL<;O_93Z9=4LC4T_P`QO-7`P-LK%IAHZQUF?B+# M7Y=J#V+FX1^VE(J19FVVQP<"3P%0NET'.6&LJR,]$8SRE0K_*58R1++'T^TPUA=P!UUG+ M=$DPA%NW*D<91=FJ0`5`HB9,P>8#J5DL4;W4\>5@S]M%%L%RGHVN0YI-Z M54[2/"1E7#5J+QT1`XII]76<"&$`'8='S11-SR.#6UI4]I51J>KZ7HMJ;W5I MX[>T#J9WG*VIX"IYJBJ/.+AJX4*BARHX_JJG/Z92)Y9I!C"IX!T;!-?K[CY> M>I#9Y%KM4IF0\93,$=*$JCF46C9*F6%BH5C,@$ MLXT^F*U]/$%PKR!I[U?7RZY"Q'%CCIEC.\N1LZ3Q_4WDA#1KM51-&;M+D?>% M7@A](2K=,M..4$3='NP(81#RU7R31PPNGD-(PVOMIA\5M#>^Z[;9>TKK7YG- M#;<'CS=P:/:5%3VJ^[)E/G7F6]XKRA0\=TP:[C?Z:P3FF.IY9W)O&5ACH>79 MN4YAVY*"+9"1(;VVG8R21WNH6D4L3LKPZ0`M M(.4@CCQP7[83E=QDLL?9Y:O<@,/S<72HO!0G.V@%3B,`IK/>.UM19/)8W]M*RV8'REKP M]=4+SIX8'VZ>57'\VX@`;98I0^)@W*`_ZY\.H!\/;UY"^LW-S" M5F6O:%1_[A;(JUO]4LJN%1_,;BKA:K=*A>H-C9J59X&W5R33%6.G:U*LIN(? M)E$0,9K(QJSEHN!1#8>DXZ]F2QR"L;@16F"R2QU&PU.V_5Z=-%/;?Q,<'#X% M=(B<_P"#IZ_NL4PF7<<2V3F*\@V>X^CKC`O+DT<11#J2B#FMH/E)9!6.33,9 M*^[BJ"#"[@=JF/\H.\^`S'R\<`*^"_' MF+D3@OC_``C6PYJRQ1\91+XZZ<>XMT\SBEI15L`"X1BF*IQ?RBR(&`3$;I*& M#2O M"4=MDDU%5%DR)(IG554,;8B:211.HH0Z\(;FWN*^@]K\O&AX*UZ;N#1-8+VZ7=0SNB^<,<'%O+& MB^V1LUX@P^G#JY6R;1<<)6!=PU@E+M9XBLDF7+0$3.FT6:7=M`?KMRN$Q.1+ MJ,4#EW#Q#4[I8F4SN:,U:5-*TXJ36=R:%MYH?K=U%;,<*@R&E0.-.VG8,54E M!P@Z12<-U"JH+D(JBJ0=R*IJ%`Q%"#_>(H%#VJ]C%H<,6D`@] MQQ"^VHHH\KM^*_QF_P`O+G+_`!)=O'1%2GL9_A30S5^"XW^L?_P"+ MZ705(N)CWX"*M%0[&/>]XP8QX04W`2F/-R2X2:*JII)*U;_4:$<+TO6@5P[$`$WI*!JV:3 M8W#XI@X$9L/:%A/2'I%KN\-D;EO'LFLG7D09;QFH#R"XT/"HQI[>]5.X*]TF MT]M:K&XF-UO0BJY;['**2D>B6M7J'-,RB8RQ%X&9;-8VY-F;E`PH.T'B9 MED>DI1$H%W]K2[FT_P#EW0.4N-#]V'!7?IAULU;HMIPV7O?3)H[-ETYHE#0. M``)J:5'/F>\J8KF]!UKNQ=NU],\1[7'7!^RL4#D2LQ*RWQ9)/YZHMY$DGCVQ M1ZAS.8"T*QDHJ""+HFWK^E_=,4^KW/'%>VQ$1%7_`+/VXKH;J58V'6_I9,_9 MUPV> MYQC)[,OY%;Z38]L#.+4?NV3M\H0RS5WU.$R`8"&,/C:F7HTVW,,H(I@*=Y^W M>M$].>OS.F^CVVS-YZ/-;-M#Z9E:T-+@,*FM*]IY]^"RB<>Y%Q%RSPF%JQU8 MXNYXRRA596(4>L1ZQ%G.QSF)EXB6CU"E5C9EB#@R3MHL!5D%`Z#@'@(Y':7# MK>YBO&XNBF:]OB%VOH>N:'O';AO-'?')IES&0,HX9A3S`<"*KR.LM8^D,397 MR?BN52%"2QKD.[4-\D=-1(4W%1LLC!"F!%``X=1&0&#?S*(:^F>BWAU#1[2_ M/&>VCD_QL#OVKC76;466JW-H:UCF>WQRN()]X5/M7-6M=NH5^M^++M4)F,^0U M:*WCYV58_1W)M427267IF3J\FDTML&J5,0,1JH[V>L3&`IEH]T@IM[H=?.K> MNU;K9FYY](N`1!F+F=[75+?;3`]X79>V-P1[CTB*_@^<@!_B./L/$8#X+'8Y M]PO_`&%^\QB+DA&IGC:;E"UT?)SXS4JB395.8=DQQF)J"NP(BJLBJ9\J7_ZU MU"'D(ZXNJV6L1R-'DDQ/MX^]<0]4[>;IK]0^G;ELQZ=CJ#XY'4P!KY'5'94. M^':KE>_+:YO-.9>%G"FD.O7D,@69*UOTFAQ72]]VZ91HM0I)O M=Q#8J9>L/#QU[ZNX330VX/F=)7W$!9E]36INW%N';73[3CGBO)HKE]#Q;)(& MBO:/*XT["J4X;KD-V]>^@WQ+7TOB7%F;*I#T^&9HD*U8'9WFHQSR#./4)4#J M(9%JJQ3;;CU+B`>)MA6X_3ZK)$!1KP/M[U9MMVL/2CZC_P#3\-&Z/J-M$VG` M>:,`>S.*KB>[BO*Y]QTX7U]RH>%J!:O5K$")C+M&#^^/$;A?YI=-N.Z!H M:@1[8#B8P=!B;;AU:\-5#;[4([(?+Q]O-4W6^:YZA];M(Z=V[BZTM1&96\@X MO=(\^/HEN/8%VW"M&^^#YH93B\BS<]$\).)AHZGT+"D'+O8F%G8^+[9$Q$^L=>MK+^JF=&/\EF`'/`TQ5;MJRO.O/4 M>[M]3?)'TYT-HA9;!Q;F+!D'RTJ26U)PPPX@4EWO_9S[>5VISRHMN/%7I*YF M#IK&6FGN9N)M$,Z52,5*41D0EE@D7#=0>H2.RK)J``E,&PZN[K6VDB]![6YC M0@CW+?FJ]`.E>KZ7_2OZ6VUE+2V.6,EKP0,"37S8T)!XT4%''G*>8.-"AT&;U` M11*4AQU8&FY9,78U.(]G[BJ/H9H'2 M34.GU]=[]$?ZH7(^>4MEI0TR`.!H<0:<>:O;_EXY.]N)CE3$UQY:W_%J*EX[ M_9@K:0>E2;6)6=GP11B$W)UFR,DXI:38\NDV.!$W/I]10,8=>^CLN?T<@).6 MII]O!;%^E&XU22\UX,-Q_I$R1_I/4)(&+_EK7'+3V4Q7!?R^+=,N>^X"*9") MB:=KG5T$(3K/]/LG&%138NQCF-O_`$!IM_.VZE$G']ZM_P!*$UT[7=UVI>YS M6NM^/;FN!A[*J\O^82Z313:"FU M=^LFL4@'((:I`\VE\+.M6N^P6*[(DU_HUUD9TXEO7WFV-2'\GU'$EI/R\:XB MN-._$X+N'\R3D11/'O&3$3!90SJQW&YWY[')B`BO]'85G7H,YTM]S;R%F6`G MAY@.VIM?G_30,B;QN:YOC,[P8?2__8:*WGC=5U.V M?W7\*4%;U8S&G)?">.*V]3*)T6(3%RJ\:W*HX]\&$3JLLN5P_B)MR`_-X%`V MPRQ0ML;QD;<&2LI[33]M5C.TK3_9/K'IVDR.IIVI6#8SV9WB,D^QU5VJM=X7T M:&XA=]67P+70!G55*S.4.-*4WI@Z2?XCK=N:JJ`HX^UJD ML&LL=3DMV8U`'O6$].='M^G7U*S;6LWG]-+;>D!_%6%LW_5K14OI%`X59`[K MG.Z%YNR5/AL:(6K(S^O/+G<75(8J7DMV@44D6LFS>QRCIZ:'5=&],5!]P`F\ M=>;(;>2]=++[@K8<:S5TD./?O&]-Z1DQY>'1*FC;8A=H=_'.YB339-3RX M`450(43&'IW\=5UU^@992_I'`ORXTXTJ/W+<.X=`Z6:#TYW'+T_F!U'^G,$I M9(YY##)$1Q.%3EJ537M6=K/ACRDX84O,.8<B70?IQO;I MY9ZYN&WNI=2E+PYPF>WG2H`=R'[%3J[4>V=E7GG@93%N0+=.\3.1,PE%3./) MB1=/$8I@>;C*Y.,':*AS,'\M5SSS61CY)%-!THB!TENK?<9YGC3KML$9/I./ M!4]SHEU]/W4S26Z'>SS;-U29S'12.-&EV84()(P-"#QX<,52O!=SA\;]]3DK MDB9;IA$42=Y>W234231!TJQK>.[#,.2E.)0`JCA!L)"COXB8-_'QU2N=-'KT M[6DY`1A_^(.'BL1VSK$&E_4WJNM7;Y'06T%W*&@X$-M)"!Q[!AWT52^W;Q>- MW;,P9IYD MM:W6GV'Z6[M96/8Z)Q;5S""TNH<<0/8N/[OG*PW%3A3?'G M0622>LG5ACW(6.Q,RF$%`^C]32<*%.F43)NE$`\S!J&IW`M8ZU7SCXD-[](G0Q]S/ MP73F=N4](S!G$6*\&0]Z1DF+DI"BO1+:+'K4-LJ5O(*]7AOJQV[!I=UZ)^66 ME?;^'[%R]T_L=:Z']0M%GUR:672-P6[?4S'RLDE)I7^Z7-*N]_F342+U3AP5 M9--7IR!DXQ#*D*;HZHRD%V`#;@(^.X^WX>.JS6FM:;<4IYG(-&T M)D\CB7W-W0LXYQY!Y:NPJ6,]B['TTM9I M\`!-#"SC_<"[#KU5R'H MBL7_`)E(X$P!QLWW$!S38=P+OO\`^SR;#?P]KJ_W=8_N%LAMFF,EI!/#V+C? MZRG-&TM+HX-F-X^G:12/,`>SA7M4D7"CBWQHF.+/&6XRG'O"DI:WV$\:RS+Z37K$3EO)./N/.); M=DZY.&-6Q_C6LR,])@T0:-$46$:@*B49%,RE1;F?R*H%;M$"`7U5U"D#Q'5Q M>`UA+30T6S]3UC2-K:++JFHY8-.MV$T:*``<@!11+\B>X5VF^1_'&VDR=D&@ M7E*7H\HHQH\Q69/_`&K1E@XLYYG6Q='')&'2M>104JTT=WAW M!1;]D+)T?Q2P7S&Y89@?SD%QX9'QW7HXB:0KA;KJW>2J2Z588+*H-9J>:LI% MHU5,B81.HKTB.Q!`M)I<]O#'*YQ\E12M:<\`/;P[EIOZ:=9;L3:VN[PULW,. MW63PB-I:#G!]0DM#G#%HI4#D5(ASKYR=J3D/Q7R>E/Y!QUD^YO:/+*8_AXZO M/RY6CKL9@;Z-_$SUS#,Y2".DW%>K`L[58H1)4?269/'CENW,X M2W274:"`&,)!'4-"AF9"1.YSJG#,:_>O'Z0-(UBPV??2WWJ,TZ:YK`'UQ;YL M0#P%"/>L4?OX86'"?=)Y(((-C(1&4W%5S7#B+?T$#DO\(@><][;%`BA4[1'O M"J&+_P"/G_`%!K;#&E@+'8NJ3[\0M=M-:GO0-]_#_?V\/9\M3% MK7C*X5%1^X^SBHYLGF^V."G"[%7CQNY$R$!3LHJ/'2Q&%# ML22RS6G933)U&011B'#L6!P^W>LK_\`F`\$-RF#+>PECR+$"NT5\=9'(UKDTY(X2`WK,V\LK&/"G*)B`0@G#P`1#@/5 M;.MB);@N;<0''B'5#J$=JN/U4;7@U;I_'NBQ&?4=/GCD:X?,6%P)`=Q#,0:# M#%1^]IUS;.=G<70Y,Y(CC'8\;\$4:";$-ZKUE]*8BIL<<5==1=P!P3D'RA)> M8$G@<%E.KS)OJATYS;ZZ%\*Y0T`5Y&E/9VGO6G^@MY>]4NJ$>[M6:'1:/I[& M-S"HS"/T6@5J,#YP1P(S"A*KQ_,&TN3QSDKAURYK"2R4Q3;,K5'CMND)0^,Z MK,L'WK)?JHT^?0MPZ M'U$L122.5D,E!_WY%-)6N M8$SW)'=T?+"\>Z&`3:-Y63F:=93BW242%50['U,]!NJNJ:=O2.=N@:D\N9<-#C&,SBX.-#WXG$ MC'#!3UY`[G7`^@TUW='_`"?Q+/MV3-9^VA*A:H^T6F5,F@*I(V.@(=9U(>_' M1P!,HKD23(`7-<#)3#O_!=.ZKUBZ8Z3I?]8O=5BFB%3$V, MDO<:"C0`!C_>HL<_CQ3[_P`LKWW(^Y/9Z?*T[&TEQ[S_`!F/B23-1)K.2UHH M+VMM&<4\7(FG*)U.FPQ!?N4-TC/G12%-[DP:M$D]S-(^[=&&QAI`//&@I7[< M%R#M+1]7WIJ>[NK>HVYMM'_IEXR(.93U/5@U/1^:G M;TO.5ZPK*PW)6"R3=8>ERAIA?Z,6*/K<)6'S.GR\0H)FC/XS4>N4DGZ(I+(K MJD$XF3`0U"PTZ*^L'.<`'DFAI]O>K7TVZ*:9U+Z0W&L:;F;O""]G$6;!D@;' M$YK'5J*5.%0:$G#&JE@[.//EI=8I;A#FFJ0F),^89CWT!789*%9U`U[BZL06 M4PWSMPQ6^^@'42 M34K&XZS/R?P'QJSGS:?9WRK4 M<6MK988IO6E+6[79DFCP]XR&XE2-/0;.!479HR"`F`VP_P"*&V_CM;=-N[2W MNIC*+-VX$4<- M$S'*`;ATA[>IM?GLKBQ'INJWU65(K3FLZ^I7>NV]Y])77.V+R.YMX]3MVRT: M:M)CG(XM'\)]RK[P\[GO!#$G#;CQ3[SR2IL);Z#A"C0EIJI6-F>SC&STWEU6M%6TR4!\#S'!6"<8)ZV=T'NW1/,.`ID[5^/?'N/9 MHPD])LQ3*^&J,YEI3H9Z]W,P-9[%.V)Q).6;&/\`J=X+ MMK2ZEW M9.O/_=YXM\?FXJN&-;_V*5=\W2,98R0V^Z+7*RF%,=R)'"M$1$VWD4FX^`!J MEUA[I=1BM'4+13CC\QXX_:BM775D^[>O>E[4MWM+8O3J'8AN0BXL>I['QMH>P!*-3(1NX,'I M%6C&"4G*](`!B*J%'8-P$:#2R_4M0.H2@AH&'8.S!81T,DN^KG5N[ZB:Y&X1 M6%LUL8>,`^C6M+0)P[^U?7G>J&'>_)QPR1U&:,+3,+3>1FE>6RY",)VO*6T M;[6U4?B]E(QDH@A*_$J3H`5*0IO2$Y>KW6P^,0L8KQT=Y0D`5J,%CNU+[IY: M===R3=1!9/TH^OE;<0MFC#_691P:YC@'4J0:5J2>]2.Y!AVK0\!+A7#6.*29?'3B,@XI1Q'A)"'20QCE*KX[!YZN4[M+? M:R"V#`0S&C0#2HY@`TJMV[RO^D]YTUUYO3D::+[^G-,OZ>!L3C'ZD=,Y#&YA M7+0$GDJ1=HKN`\-N/?!RBXRS+G^DT&^1-GR'(R-6F"3BLDT92EGD'T>L8L?$ M/4#>_&ARJ%`#B.Q@\A\->6EZA8P:>TN?3+7MXU^W!8WT#ZN=/]M],+;3=PZL MRWU"-[_Y9:\N`S8`96GB.&."M>SIEQ;O&]PCCUCO`==L#W`''Z=3E+%DAU%. MD&JT8G88FQ6FU/>LH$B&,HA7&D=#MW(E=.E#^H9,H'Z2T5Q(=5NFRQ-HQIK6 MGQ[EB.O;BF^H#JAI-AM>VF&V])E+Y)Y!1K@TDEPK7C@!SJJ98=H<=E#O@\I< M7/E5&D;D%YS#HSIWT"91NWL>-;!#^^BE,&QE6AW`*![&X!J0.F;KVNX@75J'&SD:<<<,V([N"K5VD^5]8[>>0LY< M&^8QPP^Z4ORUFJ]WLZ"D97?CUM'L:L\0DWJB12MH2V140R?Q4EU"S5'UBF.4 M0WU7V=S'#.^*YP'(GVU'-9IT,W?8]'-6U3IWO4NM(WWQE@G>#E>7-8W(2!@` M`TCD">0*R$ION!\)X&2J4&[Y185<2]YF(ZOU=E%WJ'FUI24E5R-(]$WQ*O(% M8)/'2A4RKN110ZS`7KW$`U=&W5EF`S-J3A3''[=JZKFZE[$AO(;2;4[0UMYM6ES*N."H9W0N3++E;P?[;^85WK-6Q+3.2J]D%%%TIK"81,C M[X69^_2%/L;TG!1]D->&J7;)X+=SZM(<>%1C@L6ZZ;QL-Z=-=G:X,)C-*V?` MU;D;`#7MS5J>WV+(L@NZ1V^&4!"M77+'%"2S2&BT5D3RL@!TEF[!NFLF<0C? MNLK'K9TK;;6]K)K,!N!`QI9EDS9LM M*5R8.KW\>:D08/VLLQ:2#!R1RS?MFKUHY2,/IN&CM$KANNF(@`^FNBH4P>`> M`ZN5`TUI@MP03131,NH3FMY6`L/:#B#[58#=NO[USC,/AU_=X%Q;QW#, MD@!'?BL8W-LW;&\8([? MY7O3]/M-*M([#3V"*SB:&M:.``X`+\E\Q[2LH5.9HN0ZS"W&GV!M[TF:[86" M$E$R+?J`X$%2LH-3E$?`2^!1#PVV MU2&PLB\R&)F8FIP6HW_3STD?>?K/Z4P.S9LH>_)X!M:`=P5Z4[QIP39\5-<' M6#%E)E<1,&K)G'8^QM[4 M@`QMRCDMDW&T=LSZ(S;IL;;^CL%!&6-*LM0[,7;<;V$EA+QNA5#IG M(HG"N+1=W%;*J0_J%/\`$JUC.U.`'_N&ZD]O#IV\->8L[4',UC0:K7<7T_\` M2B&__J#-*C]6MT3 M!)LS9LFI$V[=!$@;`4A2A^C?<1]1&`MNVEG9V%JRRL8VPVD8`:Q@R@`=E%A; M?S9V!/1L?%+DXP;'%*097+!UK>D3-L1Q'K?3>G$<'W$A?52"PWQ'?QV_\0:ZH M:\RO,APJ&_!H"Y]RAN`-<*^]::G/"GH!(8`%,W@=/8H@H02B4Q#@ M<#%,4P#Y"`A_:.J=MN1&(GN+HR?,",'#L/VART7BK=;*Q27-?QFUM!ES)9APBPCP!_29!SZY5I&TX^:(]'242N',,5 M)7?J15'7'76OIPS2+M^Z-+C+M(F)_BIVX=(=/=P6F[=(=M M;T5-`LESC]Q0X\<7F5EC^/\`BFKXM8VY['OK*C6R MOQ^/'44W7;QZKY21>O53>\TG:I2%*)2AUF';<1'7/T#;=L7_`*9K6PG$4%.[ M\5LC;NS]M[4]6+;UE#9QO=YL@^?F":KLN;^/&&.2-.0Q]G/'\%DNF-IAE8$( M"Q)N3M$IJ.3<),9)([1RU,`[M[?BMF$>.V&.-U07H."Z!`XUI[J8=V!Q!5]%P5HM M-/TVZ#R24,\<.ESN7"#1(@B)]@*F```;:GC].,4C:`.[!2Z#MC1=K6!T[;D$ M=I;%^8A@XG#C[ER>6<&8DSM47-#S!0:UD.I.QZE(:S1B#]%(_P#\VX-O:+NFT-CK]M%T$^P\1["K+X#M M!]N>M3J%BC.,%*/(M'*+MH24D+5-1K5=NH"J1DHJ5L#M@)`,`;D,F8AO9`0\ M-44>F6,;\[8VU6M;3H%TIM+CUV:6QPK7*]SG-KVT)/8,.&"ONF<;4BP424QC M*5N)6Q_-5U[49.HMV23"$<5J19J1[Z%(SCP:IMF+EFJ9,Q$NCW(^&VJZ@+/:K&95OK6,96 MR_-H9I])IEO#M!81R;B14*H=,&[,>@12!,RH``JB<0`0E$$8F,P`#B,<./M4 MD6U]`M]5DUZWM8F:Y+'D?,&C.YO8K47_:9[=4J]>R4EQ2QJ[D))Z\DG[L MX6(BKE_(.57;QT?TYXH`HX<+&,;;PW'P\->4MC9S?/$PGP_>L2FZ.=-+F1T] MUI%I).]V9SBTU+CQ)QYKMC+MJ<&H['D_B9CQPH+3'%JM$%=;%44"39(N7M59 M9O8Z`FWG^N11;"2723V4`O2J.X".VTPLK(1>D8F%E0?:.'WJO;TOV!'ID MNC1:7;-TV:5DCX\OE+XPX--.WSN]ZZ<3M)=N-,Y5$^)F,`,F8#H]:4^J1)0! M$>LJ:DX8@B(C[(#J62QLY6AIB9AW*W,Z-=,(WR/;HMA61M,8P:>%:J^:HX_I M]`KL=4:/78:HU:(;D;1E>KL:TB(=BD0H%#T&+))%(%#=("8X[G.(;F$1U6QD M1-RQ@#P6Q-*L+'0K.+3M(ACM[")M&L8T-`'L"H#)\'^+TQR`C^4S_$\(MGZ, MDFTLUR1[\FRROOYG!&K+199D$K\3+"W@C>]R[MO```WZWCJE?;1/>V5X_FM- M:\\.`/AR6+3]/MHW&YF[PFLV'<+7`B6IK@TM&&(P!]M!55DRMB#'><*#/8OR MO5HJ\4*SIMT9^M3:*BL?)(M'2+UJ18$%D%R"W=MR*%,0Y3`8H>.JE^22K9&A MS".!X>*ONKZ'I>N:;)I6IPLFM)&M!#A45;2AIV_BNE8*XLX"XRP\U`8$QC6L M8Q-DE$)J?9UY%YT2\JU:@Q:OGJK]Z\$,$<$9CB`:": MX*GT/;&@;:BDAT.UBMHY6M#PP4#LO`GO76,L<*.,.=,E53+^6\25Z]9&H[6- M9U6RS*\QZ\0WAYR;DK:91;E<.5`W,!"%+[0:D=:VLCLTD;'.[PK;J?2;I MQJ]U->WVD6K[J0X18\A,@UNE<=J'78+*U7)2LC1;$D MS[UMM43>)R)(24*M+JB+4)!$BVY!(?K+Y[;AI':VL0<&1,`?Z&R]/T_2CI6O!6K_9+I:2*Z+9%E"*9.WG6O%7DXNPKBS"559T MG$5%K6/*JQ*4$(6L13:.:&,4=P5="F45W[C_`-(N=13_`,K57$V.%F2-H#>[ M!9QHFW-&VU!^ET"WBM+;+3+&T#VD\3[52JM<*.+U-S;+++>%LIE+6EY/'G[U;K; M8^U[363N*&TB;KSL^:<"CW9VEAKRX%?IY`\-.-/*=C',\^XEJ^1E8?U/BB6D MT'+&?B_5#8X,9V((ZFDA@E-7L![.Y2[EV'M'>`'^HK M&&Y884)#ACB,.*H?A7M4\#N/]OC[]CC`<`WN<.NHZA;#8Y*=MSJ&< M*%,0R\6WL3Z3;,=7F*2GZ9>(*3K-H@W M1UBH2D),-CLY)B=5!5)P@5PV4,4#)G(=,1ZBB!@`=>LP]=N4X"E%<=1TRRU; M3YM*U*-LNG3QECF$4J#6M2,3Q5L5D[=G"JWX^HF*K)QXQ_)X]QFYDWM'J_O2 M09L(-]--VC27?E.PD6KE\_DV[!$BZ[E1550$B[F\->)MK9[0V2-C@.%1P[_% M8;/TJV#=:5;Z+=:;!)IMJ]SHV$&@+J9CQJ:Y1Q[%3@W:-[;Q@$#<2<8&W'<1 M$EA'<=]Q\YT?,=2-LK-CQ(R)@<#7@J5O1SIBQV=FC60?4&N3$4[#7#V*0J-B MV<0P9Q</L>6H5QJHT M=EI7S=JI7V,_PIN'_P"R5Z_>]D/4%,I8]$31$T1-$31$T1-$4)W\P!Q[4S_V MQ<]@PCR.K%AH83.U;,")UG)5,?OBJ6(C4$^I0%'%->R(".Q@$H=(AL/ALOI' MK`T??MGZK\EE/6-[N6(\H-,<7`<%@W472VZEM*:C09XCF'A4@T]A7F6"("4A M@$H@(#^J'AN(]0^[WV4WZ]]P\`WVUW[E+"6.P>"?<<6^\8KC%.&;V\>U5FFW]U MIE]'J-LXB9CA@.P+U!^T_P!R.B]R#C0QR,T(VK67Z.JTJ><\>BZ247KMO3:$ M4)/128""ZU.N"93.HY8Q"](@JW-N=`PCP!U!V7<['UI]I(PC39,SX7.B*E/8S_``IN'_[)7K][V0]$4L>B M)HB:(FB)HB:(FB+JEVJL3:=RB>1[S54DU?%8DT1:@.P@.Q1 MV$!`#%`Q1$!WV,4P"!BC[(>UHH@T-5>=P-YP9>[?W(.KY^Q*X4>%C>B'R%07 M$@Y:5[)U!=+=1[33M`/'X5`7J,\1>5^ M(N:.#:+G["D^VFJ?<(M)1TP!RDK-4^R(HD"=I-L:)F$\99:X\,*+A(X!U[%5 M3$R1R'-P!KV@ZIMO4YM*U:/TY6.\N%,S?XAW'N\.(786EZU9:W91WM@[/'(* MG_A/9^Q7/ZLRN2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB M)HB:(FB)HB:(H\KM^*_QF_R\NR'HBECT1 M-$31$T1-$31$T1?D.43"H4.H`VW`0'8=^H-]M4[8_2>^5WF814`XXT4(YJSY M:8`+"_[QW8@Y?<=VY#\4:?0IZCY4J]1E[<2RY$A*:^89(B6!Z]/'0CY%( M5'#25BXM@Y]4!$/7.J'A[/3?3#K'H>W-JQ:3K@F,\9.7*"0&DD\CAB?@M%;[ MZ;:OKFMNU#2?3#'CS%V4$N]M#X>[DHL_^[5=U[_HNQ!_UYU3_FM;$_\`L!L? M^&Y_PN_%85_L]N[M@][/Q3_NU7=>_P"B[$'_`%YU3_FM/_L!L?\`AN?\+OQ3 M_9[=W;![V?BG_=JNZ]_T78@_Z\ZI_P`UI_\`8#8_\-S_`(7?BG^SV[NV#WL_ M%:E_EJNZZ!@$<78?_KSE5-_ZO\+4IZ_;'/ M`.:/VJ5OM+=NWO1=M//)9E+&&+;)QYR7(PT?G/'*6\U5NX.*749*V_3"G?6VM_+L5\*UYQ0QQ.+V@9B>*B_P`X MH5N&XTX0V&V5K;_U[%_"M>@#@[,#AV(WR\%N^F=/^M=:^78OX5J*)],Z?];* MU\NQ?PK1$^F=/^ME:^78OX5HB?3.G_6RM?+L7\*T1/IG3_K96OEV+^%:(GTS MI_ULK7R[%_"M$3Z9T_ZV5KY=B_A6B)],Z?\`6RM?+L7\*T1/IG3_`*V5KY=B M_A6B)],Z?];*U\NQ?PK1$^F=/^ME:^78OX5HB?3.G_6RM?+L7\*T1/IG3_K9 M6OEV+^%:(GTSI_ULK7R[%_"M$3Z9T_ZV5KY=B_A6B)],Z?\`6RM?+L7\*T1/ MIG3_`*V5KY=B_A6B)],Z?];*U\NQ?PK1$^F=/^ME:^78OX5HB?3.G_6RM?+L M7\*T1/IG3_K96OEV+^%:(GTSI_ULK7R[%_"M$3Z9T_ZV5KY=B_A6B)],Z?\` M6RM?+L7\*T1/IG3_`*V5KY=B_A6B*/BZVRJCW6.-#H+-7A;$[>_.)`ZX34:* M1%E.1_;T.DDDBBI$CB4!V$P$-MOTCL1>1=E[_P!KN6?_`-T -----END PRIVACY-ENHANCED MESSAGE-----